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PROFILING CELL SURFACE SIALYLATION AND 
DESIALYLATION DYNAMICS OF IMMUNE CELLS 
 
DAN WANG 
 
ABSTRACT  
Sialic acids (SAs) are a diverse family of naturally occurring 2-keto-3-deoxy-
nononic acids that are involved in a wide range of biological processes, including early 
fetal development, cellular recognition, and utilization by microbes. While it is clear that 
cell surface SAs are highly involved in the immune system, the sialylation status of 
individual immune cells and functions are still unknown. In this study, I combined the 
newly developed LC-MS/MS methods with flow cytometry and confocal microscopy to 
systematically study the sialylation and desialylation dynamics of macrophages at different 
conditions.  
First, I developed an accurate LC-MS/MS method to quantify free SA in human 
plasma with isotope-labeled standard calibration and 3,4-diaminotoluene derivatization. 
This method is capable to distinguish SA analogus in complex biological samples, which 
paves the path for dynamic SAs research. Menwhile, another LC-MS/MS method with 
direct SAs quantification was developed for high throughtput analysis. This method does 
not require complicated sample preparation and can quantify SA at 2 ng/mL.  
Next, I performed globally profiling of sialylation status of Raw 264.7 macrophages 
by flow cytometry, confocal microscopy, and LC-MS/MS. Both flow cytometry and 
confocal microscopy showed the predominat of α-2,3 linked SAs on the cell surface, and 
  v
increase of α-2,6 linked SAs after atorvastatin treatment. Moreover, LC-MS/MS showed 
total SA increased 3 times upon treatment. Further experiment indicated the correlation of 
α-2,6 linked SAs with cell apoptosis.  
Finally, I systematically examined the sialylation and desialylation profiles of THP-
1 monocytes after differentiation and polarization.  Both α-2,3 and α-2,6 linked SAs on the 
cell surface were decreased during diffrentiation, which was in accordance with the 
increased free SA in the medium and elevated activity of NEU1 sialidase. Meanwhile, the 
increase of SA expression during differentiation was evidenced by siaoglycoconjugates 
inside the cells and total SA in the cell lysate.   
 Overall, the combined approach has bee successfully applied to profile SAs in the 
cell culture system. LC-MS/MS can accurately quantify SA in a high throughtput fashion. 
The SA linkages can be distinguished by flow cytometry and confocal microscopy with 
specific lectin labelings. The SA levels and linkages provide markers of cells at different 
status. 
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CHAPTER I 
INTRODUCTION TO SIALIC ACID 
 
 
1.1 Sialic acid  
The surfaces of all vertebrate cells in nature comprise a variety of glycoconjugates 
including glycoproteins, proteoglycans and glycolipids forming the cellular glycocalyx 
layer, which was original revealed by electromicroscopy in 1967 [1, 2]. Sialic acids (SAs) 
at the “outermost” location of these glycoconjugates are known as the “functional 
ornament” of the glycocalyx and provide extreme structural and functional diversities 
(Figure 1). The two major SA core structures are 2-keto-3-deoxynononic-acid (KDN) and 
neuraminic acid (Neu) sharing nine carbons and differing at the C5-position (Figure 2). 
The variety of substituents on carbon 4, 5, 7, 8 and 9 generate a diverse family of more 
than 50 structurally distinct molecules, which can be attached to underlying sugars 
commonly via α-2,3 or α-2,6 linkage to galactose (Gal), via α-2,6 linkage to N-
acetylgalactosamine (GalNAc) or N-acetylglucosamine (GlcNAc), or via α-2,8 linkage to 
another SA [1, 3-5]. N-acetylneuraminic acid (Neu5Ac) is the most frequent form, 
  2 
followed by N-glycolylneuraminic acid (Neu5Gc) and O-acetylated derivatives, mostly N-
acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2). Among mammals, humans are a known 
exception in their lack of Neu5Gc, due to an inactivation mutation in a hydroxylase, which 
modifies CMP-Neu5Ac to CMP-Neu5Gc [6]. 
  3 
 
Figure 1: The complexity of SA layer on the cell surface. Adapted from reference 4 
with permission from Mary Ann Liebert, Inc. 
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Figure 2: Diversity of SA structures and linkages. 
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Given their remarkable diversities in structures, glycosidic linkages, and underlying 
glycan chains, as well as their exposed location, it is not surprising that SAs can mediate 
and modulate a wide variety of physiological and pathological processes, such as 
immunological process, hormonal response, signal transduction, tumor progression, cell 
adhesion and protection [7-10]. Firstly, by virtue of the negative charge and hydrophilicity, 
SAs act as biological masks, which are anti-recognition agents by shielding recognition 
sites such as sub-terminal galactose residues, antigenic proteins and other macromolecules 
of cell membranes including receptor molecules. Secondly, SAs function in the opposite 
way by being biological recognition sites for a great variety of proteins, which are 
collectively called lectins. Angata et al. proposed to group these glycan recognition 
proteins into three categories: vertebrate pathogen lectins, vertebrate endogenous lectins, 
and lectins from other sources such as plants, protostomes, etc. [3] Vertebrate pathogen 
lectins generally show more specificity on SA structures compared to vertebrate 
endogenous lectins. For example, most influenza viruses A that spread among birds 
preferentially recognize SA with α-2,3 linkage to underlying sugar. Humans are resistant 
to infection at least partly by such virus because we instead display α-2,6 linked SA on the 
epithelium of upper airways [11, 12]. Another example is the lectins, named adhesions in 
bacteria, expressed by E. coli K99 strain shows high specificity towards 
Neu5Gcα2,3Galβ1,4Glc structure on glycolipids, which is abundantly expressed in the 
gastrointestinal tract of piglets [13]. Plant lectins are traditionally powerful tool to study 
glycan structures. Their high specificity is able to distinguish isomeric glycans with 
identical sugar compositions. For example, Sambucus nigra agglutinin (SNA) binds in a 
highly selective fashion to SA linked to either Gal or GalNAc via α-2,6 linkage. In contrast 
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to SNA, the family of lectins from Maackia amurensis seeds (MAA) recognize α2,3-linked 
SA [14].  
Vertebrate endogenous lectins are usually found in immune system. The most 
studied lectins include factor H, selectins, and siglecs. Factor H is one of the first 
discovered vertebrate lectins. Factor H is a “self” identification marker that binds to cell 
surface SAs to protect cells from the alternative complement pathway [15, 16]. Selectins, 
a family of three type-I cell surface glycoproteins including E-, L- and P-selectin, 
participate in many cell-cell interactions in immunity, haemostasis and inflammation [17]. 
Leukocyte (L)-selectin, which is constitutively expressed on many types of leukocytes, can 
recognize the sialylated ligands on endothelial venules and then facilitate homing of the 
cells into lymph nodes. Moreover, independent evidence shows leukocyte adhesion to 
activated endothelial cells is also mediated by endothelial (E)-selectin which recognize 
SAs on the leukocytes [18]. However, E-selectin is not constitutively expressed, and 
requires transcriptional induction by various inflammatory stimuli. Platelet (P)-selectin, 
which is stored in α-granules of platelets and Weibel-Palade bodies of endothelial cells, 
can rapidly mobilize to the cell surface in response to various stimuli, again mediating 
adhesion to SA-containing ligands on leukocytes [17]. Siglecs are a family of SA-binding 
immunoglobulin-like receptors that participate in the discrimination of “self” and “non-
self” and regulate the functions of cells in the innate and adaptive immune systems through 
recognition of their glycan ligands [19-21]. To date 14 siglecs have been identified in 
humans, and show highly restricted expression in immune system and the differential 
expression in various immune cells, such as sialoadhesin in macrophages, CD22 in B cells, 
MAG in oligodendrocytes and schwann cells, CD33 in macrophages and granulocytes, etc. 
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Sialoadhesion, CD22, MAG and Siglec-15 are conserved across mammals, while the group 
of CD33-related Siglecs show a great diversity among the species. Most Siglecs are 
typically bound to sialylated glycans on the same cell surface (cis interaction). However, 
another cell surface or a soluble ligand with a high enough density of sialylated ligands can 
compete out the cis ligand and cause engagement [19]. This can provide insight why SAs 
are found in so many bacterial and viruses, such as group B streptococcus, Neisseria 
meningitides, HIV, porcine reproductive and respiratory syndrome virus, etc. [20-23] On 
one hand, SAs could provide the pathogen with suppression of the alternative pathway via 
Factor H, hijack host Siglecs, and get into the host cells. On the other hand, pathogens also 
use host sialylated structures as ligands for binding and recognition. For example, influenza 
virus binds to hosts SAs via hemagglutinin, and then cleave the SAs on the same receptors 
with sialidase to achieve successful infection [24].  
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Figure 3: Multifarious roles of SAs in immunity. (A) Structure of Neu5Ac, the most 
common SA in mammals. (B) The high density of SAs on cell surface imparts negative 
charge and hydrophilicity to cells. (C) Factor H binds cell surface SAs, protecting cells 
from the alternative complement pathway. (D) Selectins on endothelia and leukocytes 
initiate leukocytes rolling on endothelial surfaces. (E) Siglecs on immune cells detect 
sialylated ligands and can inhibit immune cell activation. (F) Host SAs are frequently 
exploited as attachment sites for pathogens. (G) Microbial sialidases can help pathogens to 
expose underlying glycan-binding sites, to avoid sialylated decoys. (H) Endogenous 
sialidases can modulate immune cell functions by modulating receptor clustering, possibly 
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by exposing underlying Gal residues and facilitating galectin (Gal receptor) mediated 
cross-linking of surface molecules. (I) Microbial mimicry of host SAs allows manipulation 
of host immune response by engaging inhibitory Siglecs, inhibiting complement via factor 
H binding, and reducing the opportunity of the host to form antibodies. (J) Microbial 
synthesis of SA-like molecules, such as legionaminic acid and pseudaminic acid stabilizes 
fimbriae.  Adapted from reference 23 with permission from John Wiley and Sons.  
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1.2 Sialylation 
In general, SAs are synthesized in the cytosol and then presented at the terminal of 
glycoproteins and glycolipids anchored on the cell surface (Figure 4) [25]. The biosynthesis 
of SAs starts with UDP-GlcNAc, which is the key compound of the whole amino sugar 
metabolism. This nucleotide sugar is formed by the hexosamine pathway, which splits off 
from glycolysis at the stage of fructose 6-phosphate. A minor portion of UDP-GlcNAc 
participates into SAs synthesis pathway. The formation of Neu5Ac from UDP-GlcNAc is 
carried out in the cytosol, and requires three enzymes with four enzymatic steps. N-
Acetylmannosamine (ManNAc) is a dedicated metabolic precursor for the Neu5Ac 
synthesis with no other roles in cells. The first two steps of the enzymatic reactions are 
catalyzed by a bifunctional enzyme called UDP-GlcNAc 2-epimerase/ManNAc kinase 
(GNE) with both hydrolyzing UDP-GlcNAc 2-epimerase and ManNAc kinase activities. 
The epimerase function of the GNE converts UDP-GlcNAc to ManNAc with removal of 
the UDP moiety and epimerization of the GlcNAc. The kinase function of GNE then 
phosphorylates ManNAc to form ManNAc-6-P. The Neu5Ac-9-P synthase (NANS) uses 
ManNAc-6-P to catalyzes an aldol addition with phosphoenolpyruvate (PEP) for the 
formation of Neu5Ac-9-P. This enzymatic reaction is followed by the release of the 9-
phosphate group from Neu5Ac-9-P by Neu5Ac-9-P phosphatase (NANP). The pathway 
then moves from cytosol to nucleus where the de novo synthesized Neu5Ac is converted 
into CMP-Neu5Ac by the CMP-Neu5Ac synthetase. Lastly, the nucleotide sugar is 
transported to the Golgi apparatus by the CMP-SA transporter and is served as substrate 
for different sialyltransferases to install α-2,3, α-2,6, or α-2,8 linked sialosides into 
glycoproteins or glycolipids [26-28]. However, the biosynthesis of sialyl glycoconjugates 
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is complicated by the additional modifications on SA either before or after the formation 
of sialyl linkages in the Golgi, such as the formation of non-human Neu5Gc in animals and 
O-acetlylation in different hydroxyl groups [29-30]. 
Sialyltransferases are enzymes that directly control the cell surface sialylation 
patterns, which are typically insensitive to changes in metabolic flux because the Golgi 
concentration of CMP-Neu5Ac exceeds the Km for sialyltransferases [31]. Consequently, 
sialyltransferes are the targets that cells use to regulate their sialylation status in response 
to variable physiological and pathological stimuli. Twenty distinct sialyltransferases have 
been identified in both human and murine genomes, and all of them are type II 
transmembrane glycoproteins that predominantly reside in the trans-Golgi compartment 
[32]. Based on the type of linkage formation and nature of sugar acceptor, these enzymes 
can be categorized into four distinct families: ST3Gal family, ST6Gal family, ST6GalNAc 
family, and ST8SA family [27, 33-35]. All the described ST3Gal family transfer Neu5Ac 
residues in α-2,3 linkage to terminal Gal residues found in glycoproteins and glycolipids. 
In this family, the ST3Gal I and II subfamilies use exclusively the type 3 oligosaccharide 
structure Galβ1,3GalNAc-R, whereas the ST3Gal III, IV, V, and VI use the oligosaccharide 
isomers Galβ1,3/4GlcNAc-R. The enzymes of ST6Gal family comprise only two 
subfamilies, ST6Gal I and II, which both use the Galβ1,4GlcNAc-R as the acceptor 
substrate. ST6GalNAc family catalyze the transfer of Neu5Ac residues in α-2,6 linkage to 
the GalNAc residues found in O-glycosylproteins (ST6GalNAc I, II, and IV) and 
glycolipids (ST6GalNAc III, V, and VI). The six members of ST8SA family mediate the 
transfer of Neu5Ac residues in α-2,8 linkage to other Neu5Ac residues found in 
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glycoproteins and glycolipids, among which ST8Sia II and ST8Sia IV are 
polysialyltransferases.  
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Figure 4: Overview of mammalian SAs metabolism. Adapted from reference 25 with 
permission from Oxford University Press.  
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1.3 Desialylation 
Sialidases are a family of exo-glycosidases that catalyze the hydrolytic cleavage of 
non-reducing SA residues linked to the glycan structures of glycoproteins, glycolipids, and 
oligosaccharides. They are widely distributed in nature, from virus and microorganisms to 
vertebrates, but absent in plants, insects, and yeast [36, 37]. Four types of mammalian 
sialidases have been identified and characterized to date, and the classification is based on 
their subcellular localization, namely the intra lysosomal sialidase (NEU1), the cytosolic 
sialidase (NEU2), the plasma membrane-associated sialidase (NEU3), and the lysosomal 
or mitochondrial membrane-associated sialidase (NEU4) (Table I) [38]. NEU1 is 
ubiquitously but differentially expressed in tissues and cells, and has been purified from 
many sources, such as placenta, mammary gland, brain, and liver [38, 39]. In human 
tissues, NEU1 generally shows strongest expression, 10-20 times higher than those of 
NEU3 and NEU4, whereas NEU2 expression is extremely low and only reported in a range 
of tissues such as placenta and testis [40, 41]. NEU3 shows the highest expression in 
adrenal gland, skeletal muscle, heart, testis, and thymus [42]. NEU4 has the highest 
expression in brain, skeletal muscle, heart, placenta, and liver [43]. 
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TABLE I: General properties of four mammalian sialidases. 
 
  NEU1 NEU2 NEU3 NEU4 
Major subcellular localization Lysosomes Cytosol Plasma membranes 
Lysosomes, Mitochondria and ER 
Good substrates Oligosaccharides, Glycopeptides 
Oligosaccharides, Glycoproteins, Gangliosides Gangliosides 
Oligosaccharides, Glycoproteins, Gangliosides 
Optimal pH 4.4-4.6 6.0-6.5 4.5-4.7 4.5-4.7 
Proposed major functions 
Degradation in lysosomes;  
Exocytosis;  
Immune function; 
Elastic fiber assembly;  Carcinogenesis   
Myoblast differentiation 
Neuronal and muscle differentiation; Apoptosis;  
Neuronal differentiation; Apoptosis 
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1.3.1 NEU1 
Studies carried out so far have demonstrated the distinct target substrates and 
biological functions among all these four mammalian sialidases [44]. NEU1 is the only 
sialidase that functions in a multienzyme complex containing at least two other hydrolases 
including the glycosidase β-galactosidase (β-GAL) and the serine carboxypeptidase 
protective protein/cathepsin A (PPCA). In acidic condition, such as lysosomal 
environment, PPCA can promote the formation of NEU1 oligomers, which are catalytically 
active against sialylated oligosaccharides and glycoproteins with a preference for α-2,3 and 
α-2,6 sialyl linkages [45, 46]. The role of β-GAL in the multienzyme complex is not so 
clear, but it may provide a means of regulation of their activities, or may enhance their 
stability. NEU1 is crucial for the lysosomal catabolism of sialylated glycoconjugates. The 
defective or deficient enzyme activity is associated with two neurodegenerative lysosomal 
storage disorders, sialidosis and galactosialidosis (GS). Sialidosis is caused by structural 
lesions in the NEU1 gene, while GS is a combined deficiency of NEU1 and β-GAL caused 
by the absence of functional PPCA [47, 48]. Except the well-studied lysosomal catabolic 
function, the emerging studies mainly based on sialidase deficient animal models have 
revealed new roles of NEU1 in diverse cellular regulatory pathways including exocytosis, 
immune function, elastic fiber assembly, and carcinogenesis. 
 
1.3.1.1 Exocytosis 
NEU1 negatively regulates lysosomal exocytosis, a cellular process for the 
recruitment of lysosome to the plasma membrane, resulting in an increase in extracellular 
proteolytic activity [49, 50]. Neu1 (-/-) mice showed enhanced secretion of lysosomal 
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proteases and glycosidases and an increased presence of heavily sialylated lysosome 
associated membrane protein 1 (LAMP-1), which was identified as a target substrate of 
NEU1. In contrast, silencing of LAMP-1 expression in the cells leads to normalization of 
the LAMP-1 distribution and reduction in lysosomal exocytosis [49]. Furthermore, the 
increased lysosomal exocytosis in Neu1 (-/-) mice was linked to reduced endolymphatic 
potential, dysfunction of transduction in sensory hair cells and hearing loss that were also 
observed in sialidosis patients [51]. Interestingly, a recent published study showed sarcoma 
cells gained invasive and drug-resistant abilities by inducing lysosomal exocytosis [52]. 
Down-regulation of NEU1 and accumulation of oversialylated LAMP-1, tumor cells 
exacerbate lysosomal exocytosis of soluble hydrolases and exosomes. This facilitates 
matrix invasion and propagation of invasive signals, and purging of lysosomotropic 
chemotherapeutics. These malignant traits were reversed by inhibiting lysosomal 
exocytosis in Neu1 haploinsufficient mice. 
 
1.3.1.2 Immune function 
Cell surface SAs are implicated as potential modulator of immune cell interaction. 
It has been known for decades that sialidase treatment could substantially enhance the 
capacity of resting B cells to stimulate the proliferation of allogeneic and antigen specific, 
syngeneic T cells [53, 54]. It is suggested that sialidase treatment may be an analogue for 
an authentic step in B cell activation, which shows specific loss of α-2,6 linked SA in highly 
activated B cells. Moreover, different studies have shown the NEU1 on the surface of 
activated T cells is essential to general cell surface desialylation and to production of 
cytokines such as inerleukin 4 (IL-4) and interferon γ (IFN-γ) [55, 56]. Further, the 
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presenting of NEU1 is required for T cells interaction with antigen presenting cells and 
converting the group specific component protein into a factor necessary for the 
inflammation-primed activation of macrophages [57, 58].  
Our study and several other studies have demonstrated during the differentiation of 
circulating blood monocytes and monocytic cell lines into macrophages, the NEU1 activity 
is dramatically increased, while NEU2, NEU3, and NEU4 are unchanged or even reduced 
[59-61]. In this process, NEU1 and its activator PPCA were first targeted to the lysosome 
and then sorted to the LAMP-2 negative and MHC II positive vesicles, which later merged 
with the plasma membrane [60]. In line with this finding, the genetic approach showed 
macropahges and immature dendritic cells from NEU1-deficient mice presenting increased 
sialylation of the cell surface and compromised ability to phagocytosis [62]. As expected, 
this phenotype was reversed by the exogenous NEU1 treatment, which can affect the 
transduction of signals from the Fc receptors for immunoglobulin G via desialylation. 
Another NEU1 regulated immune receptor is Toll-like receptors (TLR) that play key roles 
in activating immune response during infection [63, 64]. Ligand binding to TLR-2, -3, and 
-4 rapidly induces NEU1 activity that promotes intracellular signaling [63, 64]. This 
activity is speculated due to the removing of SA from TLR by NEU1. Later study reveals 
a broad repression of TLR function by Siglecs and a sialidase-mediated de-repression that 
allows positive feedback of TLR activation during infection [65]. 
 
1.3.1.3 Elastic fiber assemble 
The elastin-binding protein (EBP), identical to a spliced variant of β-GAL, forms a 
cell surface elastin receptor with PPCA and NEU1. During the formation of elastic fibers, 
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the EBP initially plays the role of intracellular chaperone for hydrophobic and non-
glycosylated tropoelastin, protecting it from premature self-aggregation and degradation 
by elastases, and facilitating its extracellular deposition on the microfibrillar scaffold [66, 
67]. The cell surface-residing NEU1, which is presumably activated by the binding of EBP 
tropoelastin complex or free SA generated from undetermined substrates [68], catalyzes 
the removal of the terminal SA from carbohydrate chains of microfibrillar protein, forming 
the structural scaffold of new elastic fiber, unmasking their penultimate galactose. The 
exposed Gal then interacts with the galactolectin domain of the EBP, thereby inducing the 
release of transported tropoelastin molecules and facilitating their subsequent assembly 
into elastic fiber. Further studies with NEU1 deficient fibroblasts from sialidosis and GS 
patients showed significantly less insoluble elastin as compared to control fibroblasts, but 
had increased levels of soluble tropoelastin [66, 69]. This phenotype was reversed by the 
addition of exogenous sialidase in the medium.   
 
1.3.1.4 Carcinogenesis 
Altered sialylation of tumor cell surface glycoconjugates has been described to be 
highly associated with the metastatic phenotype of cancers. In particularly, decreasing 
NEU1 expression is one of the characteristic features for multiple cancers, while with an 
inverse correlation with metastatic ability [44, 70-72]. The level of NEU1 activity and 
expression in different clones of transformed rat fibroblast 3Y1 cells and mouse 
adenocarcinoma colon CT26 cells inversely correlated with their metastatic potential [73, 
74]. Those transformed with v-fos had lower sialidase activity and higher metastatic 
potential [73]. Further study from the same group demonstrated that overexpression of 
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NEU1 in mouse B16 melanoma cells reversed their metastatic capacity as detected by the 
suppression of the pulmonary metastasis in mice, invasiveness in collagen gels, and 
motility on colloidal gold-coated glass plates [75]. Another work showed that NEU1 
overexpression in colon cancer HT-29 cells significantly reduced their liver metastasis 
potential in mice as well as migration, invasion, and adhesion properties in vitro, whereas 
NEU1 silencing caused the opposite effect [76]. One of the target molecules of NEU1 has 
been indentified to be laminin receptor, integrin β4, which undergoes desialylation and 
decreased phosphorylation followed by attenuation of the focal adhesion kinases and 
extracellular signal regulated kinase 1/2 (ERK 1/2) pathway, and downregulation of matrix 
metalloproteinase-7 [76]. Interestingly, a microRNA, miR-125b, targeting eight transcripts 
including NEU1 as metastatic suppressor, was found to promote growth of prostate cancers 
in both intact and castrated male nude mice by down-regulating pro-apoptotic and tumor 
suppressor genes [77]. Although many experiments do not identify the molecular 
mechanism of the observed changes in metastatic capacity, they implicate NEU1 as a 
negative regulator of malignant properties of cancer cells. 
However, NEU1 does not always act as a cancer suppressor. A recent study found 
that NEU1 was expressed in a higher level in ovarian cancer tissues than that in adjacent 
normal tissues [78]. The inhibition of NEU1 with siRNA can effectively prevent the 
proliferation, apoptosis, and invasion of human ovarian cancer cells, which was speculated 
by targeting lysosome and oxidative phosphorylation signaling pathway [78]. Moreover, 
in another proposed signaling paradigm, NEU1 was activated by an epidermal growth 
factor receptor (EGFR)-induced G protein coupled receptor signaling process and 
metalloproteinase-9 activation. This tripartite complex of G protein coupled receptor, 
 21 
 
MMP-9, and NEU1 forms an alliance with EGFR tethered at the ectodomain of the receptor 
on the cell surface. Active NEU1 in the complex with EGFR hydrolyzes α-2,3 SA residues 
on the receptors, enabling removal of steric hindrance of receptor association and allowing 
subsequent dimerization, activation, and cellular signaling [79-81]. Subsequently, 
therapeutic inhibiting of NEU1 with oseltamivir phosphate at the EGFR level disabled the 
intrinsic signaling platform for cancer cell survival in human pancreatic cancer with 
acquired chemoresistance [80, 81].   
 
1.3.2 NEU2 
NEU2 is the first example of a mammalian sialidase that cDNA cloning is achieved 
based on the peptide sequence of the protein purified from rat skeletal muscle, where it 
shows predominant expression [82]. Overexpression of human NEU2 homologue in E. coli 
and the purification of the enzyme to homogeneity permit its detailed kinetic 
characterization [83]. The highest catalytic activity and affinity are exhibited on α-2,3 
linkage presenting in different sialoconjugates (gangliosides, glycoproteins, sialyl-lactose), 
whereas the α-2,8 linkage in colominic acid and the α-2,6 linkage carried by α-2,6 
sialyllactose are resistant to hydrolysis. The enzyme exhibits the highest activity on 
gangliosides (GM3, GD1a, GD1b, GT1b, and α2, 3-sialylparagloboside) in their micellar 
(vesicular in the case of GM3) supramolecular organization. Remarkably, GM1 and GM2 
are recognized only as monomers with Km values as low as 10 nM, while micellar-form 
monosialoganglioside GM2 and GM1 are not affected by NEU2. 
Because of its almost exclusive expression in musculoskeletal tissues, the main 
stream of NEU2 study is focused on the involvement in myoblast differentiation.  The 
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initial in vitro evidence was obtained from rat L6 myogenic cells [84]. In this regard, an 
increased NEU2 gene transcription in L6 myoblasts appeared to be dependent on the 
presence in the promoter region of two pairs of E-box sequence, which were known binding 
sites for muscle-specific transcription factors involved in differentiation. Subsequently, a 
similar transcriptional NEU2 upregulation was observed during differentiation of murine 
C2C12 myoblasts [85]. NEU2 overexpressing clones showed decrement of cell 
proliferation while enhanced spontaneous myoblast differentiation, which was evidenced 
by the formation of myogenin-positive myotubes and a significant decrease in the nuclear 
levels of cyclin D1 protein.  The possible involvement of NEU2 in muscle regeneration in 
vivo has been suggested in the dysferlin-deficient mouse model [86]. In this mouse model 
for human dysferlinopathy the down-regulation of the NEU2 gene was associated with 
impairment of muscle regeneration. These results provide evidences that NEU2 
upregulation constitutes an important event to trigger in vitro myoblast differentiation. In 
addition, NEU2 has been suggested to drive insulin-like growth factor 1-induced 
hypertrophy of myoblasts [87]. In this signal pathway, the activation of the 
phosphatidylinositol-3-kinase/serine-threonine protein kinase AKT1/mammalian target of 
rapamycin pathway leaded to an increase of NEU2 level. This upregulation could be 
obtained by using a constitutively activated form of AKT1, whereas transfection of a 
kinase-inactive mutant of AKT1 inhibited myotube formation and causes NEU2 down-
regulation. Furthermore, the enzymatic activity of NEU2 is inversely regulated during in 
vitro myoblast hypertrophy and atrophy [88]. As expected, hypertrophy was found to be 
coupled to high levels of NEU2, whereas atrophy was characterized by a down-regulation 
of the enzyme. However, it is still uncertain how NEU2 actually functions in human tissues 
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and cells due to the extremely low expression. The biological and phylogenic significance 
of marked decrease in NEU2 expression in the human tissues thus remains to be elucidated. 
  
1.3.3 NEU3 
NEU3 is membrane-associated sialidase that ubiquitously expressed in various of 
animal species [38, 42].  It possesses specific activity for gangliosides, including GD3, 
GD1a, GD1b and GM3; whereas sialyllactose, 4MU-NeuAc, GM1 and GM2 are poor 
substrates, and it has no activity against sialylated glycoproteins such as fetuin, transferrin 
and orosomucoid [89, 90]. Interestingly, the mouse NEU3, but not NUE2, seems to remove 
even stable SA of GM1 and GM2 in the presence of GM2 activator protein [91]. Moreover, 
the activity of sialidase NEU3 is exerted also on gangliosides exposed on the extracellular 
leaflet of the plasma membrane of adjacent cells by cell-cell interaction [92]. The puzzling 
mechanism of NEU3 anchorage to the membrane was solved by studying the 
overexpressed mouse NEU3 in HeLa and COS-7 cells [93]. NEU3 behaves as a 
peripherally associated membrane protein, presenting in both the plasma membrane and 
the membranous structures corresponding to the recycling endosomal compartment, from 
which it can be released by treatment with carbonate.  
 
1.3.3.1 Regulation in membrane microdomains 
NEU3 has been suggested to play essential roles in regulation of cell surface 
functions because of its major localization in the plasma membrane and strict substrate 
preference for gangliosides involved in signal transduction. NEU3 is located in rafts of 
neuroblastoma cells and in caveolae of HeLa cells, closely associated with caveolin-1, 
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probably through the caveolin-binding region [94, 95]. In caveolae, NEU3 has been 
proposed to control platelet-derived growth factor (PDGF)-induced Src mitogenic 
signaling and DNA synthesis by modification of GM1 levels at cell surfaces [96]. 
Caveolin-enriched membrane microdomains regulate the association of Src family protein 
tyrosine kinases with PDGF receptor, which represents a pivotal site for kinase activation 
and cell cycle progression. A member of the transmembrane adaptor protein family, 
phosphoprotein associated with glycosphingolipid-enriched microdomains, induces NEU3 
sialidase activity, leading to GM1 accumulations and PDGF receptor exclusion from 
caveolae. The biological action of NEU3 is exerted through its activity on gangliosides, 
which are essential structural and functional components of membrane microdomains. 
Moreover, NEU3 is also found in tetraspanin-enriched microdomains (TERMs) [96]. 
Tetraspanins are a family of membrane proteins involved in membrane 
compartmentalization dynamics. Overexpression of NEU3 in HB2 mammary epithelial 
cells affected the stability of CD82-containing TERMs, which showed the decreased 
association with CD151, but enhanced association with EGFR. These results have 
demonstrated the relevance of gangliosides, as NEU3 substrates, in maintaining the 
integrity and functionality of CD82-enriched microdomains and suggested a role of NEU3 
as possible physiological regulator of these membrane structures. 
 
1.3.3.2 Promotion cell differentiation 
The possibly important role of NEU3 in the proliferation control and differentiation 
in neuronal cell system was revealed several years before the cloning of its cDNA [97]. 
The direct participation of NEU3 in neuronal cell differentiation was further proved by the 
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stable transfection of the sialidase in Neuro2a cells, which showed the accelerating neurite 
arborization following 5-bromodeoxyuridine treatment [98]. Recent studies provide 
important details on the role played by NEU3 in axonal growth and regeneration via 
regulation of GM1 level [99, 100]. GM1 has been shown to promote axon growth and 
regeneration in vitro and in vivo. In contrast, the polysialylated gangliosides, GD1a and 
GT1b, have been shown to act as receptors for myelin-associated inhibitors [101]. 
Application of exogenous sialidase that cleaves SA residues from polysialylated 
gangliosides to generate monosialylated GM1 has been shown to relieve myelin-dependent 
neuronal outgrowth inhibition as well as promote axon regeneration and functional 
recovery in rats that have been subjected to spinal cord injury [100, 102].  Moreover, NEU3 
asymmetrically accumulating at the tip of one neurite of the unpolarized rat neuron can 
induce actin instability, thus triggers the polarization of neurons [103]. Suppressing the 
enzymatic activity blocks axonal generation, whereas stimulating it accelerates the 
formation of a single (not several) axon [103]. Underlying molecular mechanism indicates 
NEU3 induces axon specification by enhancing TrkA activity locally, which triggers 
phosphatidylinositol-3-kinase- and Rac1-dependent inhibition of RhoA signaling and the 
consequent actin depolymerization in one neurite only.  
NEU3 also plays a key role in skeletal muscle differentiation by strictly modulating 
the ganglioside content, with special regard to GM3 [104-106]. Induced down-regulation 
of NEU3 in murine skeletal muscle cells C2C12 myoblasts, even when partial, totally 
inhibits their capability to differentiate by increasing the GM3 level above a critical point, 
consequently leading to EGFR inhibition and ultimately down-regulation, and a higher 
responsiveness of myoblasts to the apoptotic stimuli [104]. Conversely, the over expression 
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of NEU3 affects the EGF signaling pathway in an opposite direction, which promoting cell 
proliferation and delaying the beginning of the differentiation [105-106]. Regarding this 
point, NEU3 is proposed as a cancer marker, because of its up-regulation has been found 
to promote the suppression of cell apoptosis in human cancers by a mechanism dependent 
on the depletion of gangliosides and subsequent over-activation of mitogenic receptor [71, 
107-109].   
 
1.3.4 NEU4 
Human NEU4 is present in two isoforms, long (NEU4L) and short (NEU4S), which 
are different in the presence or absence of 12 amino acids at the N-terminal, and the 
subcellular location with NEU4L showing a mitochondrial localization and NEU4S in 
association with endoplasmic reticulum (ER) [110, 111]. The isoforms are differentially 
expressed in a tissue-specific manner. The brain, muscle and kidney contain both, whereas 
the liver and colon possess predominantly the short form [110]. Although both isoforms 
possess broad substrate specificity from glycoproteins to gangliosides and 
oligosaccharides, they show reduced activity towards substrates containing a-2,6 linked 
SA and branched Fuc residues [43, 112]. Interestingly, the mitochondrial localization of 
NEU4L suggests that the protein could be involved in the pathways of mitochondrial 
apoptosis through the regulation of the level of apoptogenic ganglioside GD3 within the 
organelle [113, 114]. Mouse NEU4 also has two isoforms derived from alternative splicing, 
designated NEU4a and NEU4b. However, the mouse Neu4 gene is expressed dominantly 
in the brain, and only very low levels in other tissues [115]. The expression level of mouse 
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gene increases 3-14 days after birth suggesting a role for brain development, presumably 
through digestion of polysialic acids on surfaces of neuronal cell [116].        
In addition to the mitochondria and ER membrane localization, NEU4 has also been 
found in the lysosome lumen. In contrast to NEU1, NEU4 is targeted to lysosomes by the 
Man 6-phosphate receptor and does not require association with other proteins for 
enzymatic activity. Expression of NEU4 in the cells of sialidosis and galactosialidosis 
patients resulted in clearance of storage materials from lysosomes, and this rescue activity 
exerted by NEU4 was further supported by results obtained from Neu4 deficient cells [43, 
117]. In Neu4 knockout mice model, a marked vacuolization and lysosomal storage in lung 
and spleen cells were observed [118]. In addition, gangliosides profile in the brain showed 
an increased level of GD1a and a decrease of GM1, suggesting a possible involvement of 
the enzyme in the ganglioside desialylation processes within the central nervous system. 
Unlike human Tay-Sachs disease, β-hexosaminidase A-deficient mice remain 
asymptomatic to 1 year of age, because the catabolism of GM2 can be partially 
compensated by NEU4 pathway. As expected, mice with a double deficiency of NEU4 and 
β-hexosaminidase A sufferedd epileptic seizures and rapid neuronal loss accompanied with 
GM2 accumulation [118]. 
The mitochondria localization and predominantly brain distribution of NEU4L 
suggest it may have important functions in the brain. In contrast to NEU3, murine NEU4 
appears to negatively regulate neurite formation, being down-regulated in Neuro2a cells 
during retinoic acid induced differentiation [116]. Furthermore, overexpression of NEU4 
resulted in suppression of neurite formation, and its knockdown showed the acceleration 
[116]. Interestingly, in this process the endogenous substrate for NEU4 was not 
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gangliosides but a 95-kDa glycoprotein, which decreased with cell differentiation. A more 
recent study has shown NEU4 regulated neuronal differentiation is at least partially through 
degradation of polysialic acids [119]. This mechanism was evidenced in neuroblastoma 
Neuro2a cells that were co-transfected with Neu4 and a polysialyltransferases, ST8SiaIV. 
In mouse embryonic hippocampal primary neurons, the endogenously expressed NEU4 
was found to decrease during the neuronal differentiation. Moreover, NEU4 was partially 
co-localized with polysialic acid in neurites and significantly suppressed their outgrowth, 
whereas silencing of Neu4 showed the acceleration together with an increase in polysialic 
acid expression.
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1.4 Analytical approach 
Recent studies are unexpectedly revealing that sialoglycoconjugates contribute in 
both general and specific ways to many biological regulatory pathways. This dramatic 
development demands more specific, accuracy, and systematic SA detection technologies. 
As is described before, both sialyltransferases and sialidases can reflect the total expression 
level of SA, and may reveal the underlying molecular mechanisms as well. Other more 
desirable approaches should be able to distinguish SA in different locations (such as cell 
surface, cytoplasm, and culture medium), different linkages (such as α-2,3 and α-2,6), and 
even different underlying structures. First of all, SA on the cell surfaces can be monitored 
by several methods, including lectin labeling, boronic acid capturing, metabolic 
engineering, and chemical modification [120]. Lectins specifically recognize non-reducing 
ends of naturally occurring glycans of glycoconjugates, including glycoproteins and 
glycopeptides. However, they can be very large proteins that may suffer from relatively 
low affinities, and many lectins can perturb cells by cross-linking receptors, which limits 
their application in live cells [121, 122]. Nevertheless, these drawbacks can be 
compensated by another carbohydrate recognition molecule, boronic acid, which forms 
cyclic esters with diols in different positions of sugars in aqueous solution [123]. 
Phenylboronic acid selectively binds to SAs and thus has been considered as an innovating 
molecular targeting platform for SA detection [124]. Metabolic labeling with SA or SA 
precursor analogues allows the introduction of unique functional groups that provide 
specific and sensitive detection. However, the poor incorporation efficiency rises great 
challenge for the sugar structures as well as the application in broad range of cells [125]. 
Mass spectrometry is another powerful tool that can quantify SA either with or without 
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chemical derivatization, and differentiate SA in various underlying glycan structures [126]. 
Undoubtedly, mass spectrometry is the potential answer to more complicated questions 
arised in SA research.     
 
1.4.1 Lectin-affinity approach to determine SAs on cell surface 
SA-specific plant lectins possess historical importance in investigating the 
expression and biology of SA [121]. During the past decades, lectins that discriminate 
various types of sialylated glycans have been reported (Table II). Since α-2,3 and α-2,6 are 
two major forms of SA linkages principally to Gal or GalNAc residues, the lectin searching 
has been mostly focus on these two types of sialylated glycoconjugates. Wheat germ 
agglutinin (WGA) is initially identified having high specificity towards GlcNAc and its β-
1,4 linked oligosaccharides. Due to configuration similarities to GlcNAc, SA also shows 
direct interaction with WGA regardless the underling linkages [127, 128].  The lectin from 
Sambucus nigra (SNA) shows a marked preference for the Neu5Acα2,6Gal/GalNAc over 
the α-2,3 structure, thus it has been wildly used to differentiate SA isomers on cell surface 
[129]. The Polyporus squamosus lectin (PSL) has specificity for Neu5Acα2,6Gal over the 
Neu5Acα2,3 sequence, but unlike SNA, it does not bind to the mucin-derived O-linked 
Neu5Acα2,6GalNAc sequence. The strict specificity of the lectin for α-2,6 linked SA 
renders this lectin a valuable tool for glycobiological studies and cancer research [130, 
131]. Allomyrina dichotoma lectin II (Allo A-II) is another lectin with high specificity for 
α-2,6 structure, although it shows a small degree interaction with Galβ1,4GlcNAc [132]. It 
provides a useful tool to separate complex type oligosaccharides with the 
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Neu5Acα2,6Galβ1,4GlcNAc group from their isomeric oligosaccharides with the 
Neu5Acα2,3Galβ1,4GlcNAc group. 
Lectins from Maackia amurensis provide powerful tool for α-2,3 linked SA 
structure study. Maackia amurensis lectins (MAA) consists of two molecular species, a 
strongly hemagglutinating hemagglutinin (MAH) and a strongly mitogenic hemagglutinin 
(MAL). MAH binds preferentially to sialylated O-linked glycans containing the 
trisaccharide Neu5Acα2,3Galβ1,3GalNAc; MAL preferentially bind to sialylated N-linked 
or core 2 O-linked glycans with Neu5Acα2,3Galβ1,4GlcNAc/Glc trisaccharide [133, 134]. 
Mixtures of MAL and MAH can be used to detect glycans containing α-2,3 linked SA, and 
are the most interesting complementary probe to the SNA. These lectins combination can 
distinguish among different types of SA linkages and have been used as general tools in 
the detection, quantitation, localization, purification and characterization of many 
biomolecules containing SA.  There are a few mushroom lectins reacting with 
Neu5Acα2,3Gal sequence too. Agrocybe cylindracea lectin (ACG) strongly interacts with 
glycoconjugates containing Neu5Acα2,3Galβ1,3GlcNAc/GalNAc sequences [135]. 
Psathyrella velutina lectin (PVL) and Macrophomina phaseolina agglutinin (MPA) 
exhibit high affinity towards sialoglycoproteins possessing trisaccharide α-2,3 linkages and 
as potential tools for separation and detection of sialoglycoproteins [136, 137]. 
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TABLE II: Sialic acid-specific binding lectins 
Lectin Specificity 
Wheat germ agglutinin (WGA)  Neu5Ac, GlcNAc(β,1-4)GlcNAc 
Sambucus nigra lectin (SNA) Neu5Ac(α-2,6)Gal/GalNAc 
Polyporus squamosus lectin (PSL) Neu5Ac(α-2,6)Gal 
Allomyrina dichotoma lectin II (Allo A-II) Neu5Acα2-6Galβ1-4GlcNAc 
Maackia amurensis hemagglutinin (MAH)  O-linked Neu5Ac(α-2,3)Gal  
Maackia amurensis leukoagglutinin (MAL) N-linked or core 2 O-linked Neu5Ac(α-2,3)Gal  
Agrocybe cylindracea lectin (ACG)  Neu5Acα2,3Galβ1,3GlcNAc/GalNAc 
Psathyrella velutina lectin (PVL)  Neu5Acα2,3Galβ1,4GlcNAc, GlcNAc 
Macrophomina phaseolina agglutinin (MPA)  Neu5Ac(α-2,3)Galβ1,4GlcNAc  
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Fluorescent labeled lectins are wildly used in flow cytometry and fluorescent 
microscopy for research and diagnosis that related to SA alteration. For example, in one 
cancer research, MAL was used to investigate the expression levels of α-2,3 linked SA in 
50 primary tumor cases, 50 pair-matched lymph node metastasis tumor samples and in the 
MDA-MB-231, T-47D and MCF-7 breast cancer cell lines with different metastatic 
potential. The expression of α-2,3 linked SA was analyzed by flow cytometry, 
histochemistry and cytochemistry after MAL labeling. As a result, the expression of α-2,3 
SA showed a positive correlation with cancer cell metastatic potential, the higher α-2,3 
linked SA level the stronger adhesion, invasion and migration activities [138]. Another 
study using same approach found high expression of α-2,3 linked SA was associated with 
the metastatic potential of human gastric cancer [139]. Moreover, with SNA labeling and 
flow cytometric detection, α-2,6 linked SA has been suggested to correlate with the 
adhesion of breast cancer cells [140, 141]. However, it should be considered that both α-
2,3 and α-2,6 sialylation may play different roles in regulating cell adhesion of different 
cancer cells when developing potential therapeutics targeting for sialylation.   
Furthermore, the strict specificity of lectins to glycan structures provides a valuable 
approach to identify the functional glycocnjugates. In a pilot study, a confocal microscopy 
method employed four different SA-specific lectins was established to successful 
identification and localization of cell surface and intracellular sialoglycoconjugates of 
peripheral blood cells [142]. Later, another study analyzed the expression of cell surface 
sialoglycoconjugates in Herpetomonas megaseliae by flow cytometry and fluorescence 
microscopy using lectins that specifically recognize SA residues [143]. Strong reaction was 
detected when parasites treated with slug Limax flavus lectin (LFA), MAA or SNA, 
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indicating that molecules containing α-2,3 and α-2,6 sialylgalactosyl sequences were 
present in this protozoan. Further study suggested a possible involvement of sialomolecules 
in the interaction between this insect trypanosomatid and the invertebrate host. Lectins also 
possess potential to selective detection of glycan sialylation on cancer cell surface. 
Recently, a study utilized two human mammary epithelial cell lines, HB4A (breast normal 
cells) and T47D (breast cancer cells) as a model system to demonstrate differential surface 
glycans when treated with SA under nutrient deprivation [144]. Although SA treatment of 
both cells resulted in increased activities of α-2,3/6 sialyltransferases, both flow cytometry 
and confocal microscopy showed a very strong staining on the membrane of SA-treated 
T47D cells, indicating an increase of Neu5Acα2,3Gal on the cell surface. 
Although lectins have offered important approach to study cell surface sialylated 
structures, there are still several drawbacks. First, some of the plant lectins are glycosylated 
and it will complicate the results for study the complex samples that may contain 
endogenous lectins which could interact with the glycan of plant lectins [145]. In addition, 
many lectins can perturb cells by cross-linking receptors limiting their application in live 
cells [146]. At last, unlike other more detailed analysis by mass spectrometry and NMR, 
the lectins could only get a category glycan/glyoprotein and must draw assistance from the 
high resolution mass spectrometry to identify the structure for further study [147]. 
Nevertheless, lectins actually give a hand on the research of sialoglycoconjugates on cell 
surface and separation siaoglycoconjugates especially from complicated matrix in an 
affinity manner. 
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1.4.2 Free SA quantification 
The SAs in different linkages on cell surfaces can be determined by flow cytometry 
and confocal microscopy after specific lectin labeling. However, different approach is 
required to analyze SA in other forms and systems. For example, the total amount of SA 
expressed by cells, and free SA portion in culture medium and human plasma. To answer 
these questions and to systematically study SA in different biological conditions, we 
introduced quantitative liquid chromatography coupled mass spectrometry (LC-MS/MS) 
to achieve accuracy and robust detection of SA in matrices, such as human plasma, cell 
culture medium, and cell lysate. 
The special 9-carbon monosaccharide with one carboxylic acid structure provides 
no UV absorption, which initially vanished the possibility to directly quantify SA. 
Derivatization reagents with UV absorption such as resorcinol [148] and thiobarbituric acid 
[149] enables the detection of SA with colorimetric assay. In order to improve the detection 
sensitivity and specificity, new fluorometric methods were developed with modified 
thiobarbituric acid derivatization [150], or mild periodate oxidation coupled with Hantzsch 
reaction [151]. However, neither colorimetric nor fluorometir assays could differentiate SA 
from other interference, thus limiting their application in complex biological samples. 
Reversed-phase HPLC has the advantage of quantitatively differentiating various forms of 
SAs and limits the interference from matrix. For example, HPLC-UV with per-O-
benzoylation has been reported to determine Neu5Gc and Neu5Ac in the culture media and 
cell-associated glycoconjugates from cancer cells [152]. However, the revolutionary 
advance of SAs quantification started after the development of quinoxaline derivatization 
followed by HPLC with fluorescence detection (Figure 5). Derivatization reagents such as 
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1,2-diamino-4,5-dimethoxybenzene (DDB) [153], o-phenylenediamine (OPD) [154], and 
1,2-Diamino-4,5-methylenedioxybenzene (DMB) [155, 156] are initially reported to give 
strong fluorescent intensity. Among them DMB is the most sensitive one with high 
derivatization efficiency, thus it has been commonly used for SAs derivatization and also 
in commercial SAs quantification kits. However, both DMB reagent and its SAs derivative 
are very instable due to their light and oxygen sensitivity. Fresh DMB solution has to be 
prepared every day, which is time consuming and increases the cost for the expensive DMB 
reagent. In our lab we have reported two stable and cost-effective quinoxaline 
derivatization reagents, 3,4-diaminotoluene (DAT) [157] and 4,5-dimethylbenzene-1,2-
diamine (DMBA) [158], both of which give high reaction efficiency and intense signal in 
fluorescence and mass spectrometry quantification. 
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Figure 5: Quinoxaline derivitization of SAs   
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The LC-MS/MS quantification coupled with quinoxalinone derivatization 
possesses high sensitivity and high resolution, which has provided a powerful tool for SAs 
analysis in the complex biology samples [159-161]. A very successful application is to 
study SA diversity, and identify small amount of unexpected SAs or new members of their 
family [160, 161]. One study used electrospray ionization-mass spectrometry (ESI-MS) to 
characterize SAs after the HPLC separation of their DMB derivatives from different 
biology source [160]. As a result, 28 different SAs including more than 10 new species 
were identified. Furthermore, this approach was able to characterize the sulfate esters of 
SAs such as Neu5Ac8S and Neu5Gc8S, which were not detected using other 
methodologies. Aother similar study used LC-MS/MS to compare SA species and 
distributions in different tissues of rats and mice [161]. Results showed a wide variety of 
SAs existed in tissue-specific manner in mice and rats, and highly acetylated SAs and 8-
O-sulfo-Neu5Ac were commonly distributed in all the organs examined. For example, 
mouse sera contained Neu5Gc as the major SA, but Neu5Ac and Neu5,9Ac2 were the 
major components in rat sera. Sublingual and submaxillary glands of rats showed wide 
distributions of various SAs, but those of mice contained simple SA composed of Neu5Ac 
as the major one. Although the reason different SAs are found in these tissues is not clear, 
different enzymes such as acetyl transferase and sulfotransferase play some significant 
roles.  
The derivatization method indeed provides valuable tool to identify and quantify 
(if the standard compounds are available) SA species in various biology samples. However, 
the sample preparation is tedious and time consuming, which limits its application in large 
scale sample analysis, such as in clinical case. One of the most attractive area in clinical 
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application is the diagnosis of SA storage disease [162-164]. SA storage diseases (SSDs) 
are inborn error resulting from defects in the lysosomal membrane protein sialin, which 
leads to accumulation of SA in tissues, fibroblasts, and urine. Defective free SA transport 
can be established by quantification of free SA in urine. Direct SA quantification with LC-
MS/MS has been reported to be more rapid, accurate, and sensitive than earlier methods 
for SA detection in the urine [162]. In one clinical study, free SA in the urine samples was 
separated by amino propyl guard column with gradient elution, and then detected by triple-
quadrupole mass spectrometer in negative mode [162]. This method was used to quantify 
free SA in urine samples from 72 control people and 3 SSDs patients. The results showed 
this method can successfully distinguish the SSDs from the healthy individuals. For 
example, patients at 1.2 years old had SA of 111.5 mmol/mol creatinine, compared to the 
normal range 0.7-56.9 mmol/mol creatinine obtained from 20 normal people. In another 
clinical study, both urine free and total SA were analyzed by a newly developed LC-
MS/MS approach using an Atlantis dC18 analytical column to separate SA from the 
interferences [163]. Free SA was analyzed directly after a simple filtration step, and total 
SA was obtained by one step acid hydrolysis. This method achieved a semi-automated 
sample preparation in combination with a runtime of 6 min, which made it suitable for high 
throughput analysis. Moreover, based on urine samples from 589 individuals and 11 SA 
metabolism deficient patients, age-related reference values for free SA, total SA and 
conjugated SA were determined and improved the diagnostic efficacy. Later a similar LC-
MS/MS approach with small modification was used to determine free and conjugated SA 
in amniotic fluid supernatant (AFS), which is also used for SSDs screening test [164]. The 
whole procedures from sample preparation to MS analysis can be performed in 2-4 h. 
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Reference values in AFS were 0-8.2 μmol/L for 15-25 weeks of gestation and 3.2-12.0 
μmol/L for 26-38 weeks of gestation. In AFS samples from five fetuses affected with 
infantile SSD free SA was 23.9-58.9 μmol/L demonstrating that this method was able to 
discriminate infantile SSD pregnancies from normal ones.                
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CHAPTER II 
QUANTIFICATION OF FREE SIALIC ACID IN HUMAN PLASMA 
THROUGH A ROBUST QUINOXALINONE DERIVATIZATION 
AND LC-MS/MS USING ISOTOPE-LABELED STANDARD 
CALIBRATION FORMULATION 
 
 
2.1 Introduction 
SAs, a family of 9-carbon containing acidic monosaccharides, often terminate the 
glycan structures of cell surface and secreted glycoconjugates such as glycoproteins and 
glycolipids. SAs are involved in many biological processes like immunological process, 
hormonal response, signal transmission, tumor progression, cell adhesion, and protection 
mechanisms [1,2]. It has been demonstrated that cancers and cancer stages may be 
associated with a significant overrepresentation of SAs on the glycoproteins of cancer cell 
surface [3,4]. In addition, SAs exist in both free and conjugated forms in tissues and fluids 
such as serum, urine and saliva. Also, it is known that the amount 
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of SAs in serum is elevated in cardiovascular diseases, and is a strong predictor of 
cardiovascular mortality [5,6]. Therefore, SAs have been considered as a biomarker for 
certain types of cancers, cardiovascular diseases and some other diseases. 
Because of the great significance of SAs in physiological and clinical applications, 
several analytical methods have been developed for quantification of SAs, either free SAs 
or SAs released from glycoconjugates in variety of matrices. These include colorimetric 
[7,8] and fluorometric [9,10] assays, liquid chromatography coupled with different 
detection techniques, such as pulsed amperometric detection [11,12,19], UV [13], 
fluorescence [14-20] and mass spectrometry [21-31]. Sample preparation involves either 
non-derivatization [11,12,24-29] or derivatization [7-10, 13-23,30,31] before analysis. 
Among all these methods, DMB derivatization of SAs combined with HPLC fluorescent 
detection [15,16,18-20] and LC-MS/MS detection [22,31] has been the most frequently 
used assay due to its high specificity and sensitivity. DMB reacts with α-keto carboxylic 
acid, and provides a good response with both fluorescent and mass spectrometric 
detections. However, DMB is a highly light sensitive and expensive reagent, which has to 
be stored under -20 oC in dark with inert gas. Particular cautions must be taken in the 
derivatization procedure. Further, slight variations in the experiment conditions could lead 
to a poor reproducibility of the results. In order to overcome these limitations, other 
phenyldiamines such as OPD [17] and DDB [23] had been investigated with improved 
product stability. In this study, we have checked the chemical and physical properties of 
commercial available phenyldiamines and thoroughly investigated a much stable and 
inexpensive DAT for SAs derivatization and LC-MS/MS analysis (Figure 6).  
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Figure 6: SA is derivatized with DAT, and then quantified by LC-MS/MS. 
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In the FDA guidelines for validation of bioanalytical methods, the same biological 
matrix as the matrix in the intended samples should be used for validation purposes 
whenever possible. However, the presence of endogenous SAs in plasma causes a difficulty 
to construct matrix-matched calibration curve for accurate analysis. To solve this problem, 
the most adoptive ways use water [26-30] as matrix or standard addition calibration [21,23] 
in SAs quantification. The problem associated with water is that it cannot reflect the 
suppression or enhancement of signal caused by co-eluting components in complex 
biomatrices, especially with ESI-MS [32,33]. Although standard addition can avoid the 
matrix effect, the high background of SAs in biomatrices makes it hard to accurately 
calculate a small change from a large value. In this study, we used a stable isotope-labeled 
compound 13C3-SA to prepare calibrators and quality control (QC) samples in plasma. In 
particular, isotope-labeled compounds possess great similarity in chemical properties with 
native compounds, and can provide true relationship between the detection response and 
the analyte concentration in a matrix. Overall, a good reproducibility, accuracy and 
sensitivity were achieved for free SAs quantification employing UHPLC-MS/MS and 
isotope-labeled standard calibration (ILSC) combined with DAT derivatization.   
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2.2 Experimental 
2.2.1 Materials 
N-Acetyl-D-neuraminic acid (SA, 98%) was purchased from Rose Scientific Ltd. 
(Edmonton AB, Canada), N-acetyl-D-neuraminic acid-1,2,3-13C3 (13C3-SA, 99%), 
ketodeoxynonulosonic acid (KDN, 99%), 3,4-diaminotoluene (DAT, 97%),  1,2-diamino-
4,5-methylenedioxybenzene (DMB, 98%), 4-bromo-1,2-diaminobenzene (97%), 4-nitro-
O-phenylenediamine (98%), 2-mercaptoethanol (99%), and sodium hydrosulfite (85%) 
were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Acetonitrile (HPLC 
grade), methanol (HPLC grade) and acetic acid (ACS grade) were obtained from Fisher 
Scientific (Hanover park, IL, USA). Deionized water was generated from Barnstead Nano-
PURE Water Purification System (Asheville, NC, USA). Human plasma for method 
validation was purchased from Innovative Research (Novi, MI, USA). Patient and normal 
plasma samples were obtained from Cleveland Clinic (Cleveland, OH, USA). 
 
2.2.2 Stock and work solutions 
DAT solution at 10.0 mM was prepared by dissolving DAT reagent in 1.4 M acetic 
acid containing 18 mM sodium hydrosulfite and 0.75 M 2-mercaptoethanol. The solution 
was kept in refrigerator at 4 oC.  
The stock solution of 13C3-SA was prepared in plasma at 1.00 mg/mL, then serially 
diluted with plasma to provide work standard solutions at 20.0, 60.0, 200, 600, 2.00 × 103, 
6.00 × 103, 2.00 × 104 ng/mL, which were used as the calibrators. These work solutions 
for preparation of QC samples were generated in a similar manner at the concentrations of 
40.0, 800, and 1.60 × 104 ng/mL. All the 13C3-SA work solutions were aliquoted into 50 
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μL per vial. IS work solution was made by dilution of KDN with water to the concentration 
of 3.00 × 103 ng/mL. The stock and work solutions were stored at -20 oC until analysis. 
 
2.2.3 Sample preparation 
Protein precipitation (PPT) procedure was employed to extract free SA, 13C3-SA 
and IS from plasma samples, including the calibrators, QC standards, blanks and the 
unknown samples. After plasma samples were thawed to room temperature, 10 µL of IS 
work solution was spiked into each sample of 50 µL except the blanks, in which 10 µL of 
water was used. Following a 30 seconds vortex, 150 µL of acetonitrile was added into each 
sample, which was vortexed for another 1 min, and then centrifuged at 15,000 g for 5 
minutes. Afterwards, 20 μL of supernatant was transferred to another 1.5-mL centrifuge 
tube, and mixed with 180 μL DAT solution. The reaction was processed at 80 oC for 40 
min, and stopped by cooling in ice water for 5 min. The derivatized samples were then 
analyzed using UHPLC-MS/MS as described below. 
 
2.2.4 LC-MS/MS instrumentation and conditions 
The UHPLC was a NexeraTM system, consisting of a DGU-20A3R degasser, two 
LC-30AD pumps, a SIL-30AC autosampler, a CTO-10A column oven and a CBM-20A 
system controller from Shimadzu (Columbia, MD, USA). The UHPLC system was 
interfaced to a Qtrap 5500 mass spectrometer equipped with eletrospray ionization source 
from AB SCIEX (Framingham, MA, USA). Data acquisition and processing were 
conducted using Analysis 1.6.1 software packaged with Multiquan from AB SCIEX.  
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For chromatographic separation, 10 μL of prepared samples were injected onto a 
Phenomenex Kinetex C18 column (2.1 × 50 mm, 1.7 m) guarded with a C18 
SecurityGuard ultra guard column (Torrance, CA, USA). The column temperature was 
maintained at 35 oC during the analysis. The mobile phase was a mixture of water-methanol 
(80/20, v/v) at an isocratic flow of 0.3 mL/min.   
The MS detection employed positive electrospray ionization, and multiple reaction 
monitoring (MRM) for quantification. The quantitative MRM transitions were set at m/z 
396 → 253 for SA, 399 → 256 for 13C3-SA, and 355 → 175 for IS; the quality assurance 
MRM channels were 396 → 283 for SA and 399 → 286 for 13C3-SA. The optimal MS 
parameters were as follows: Ion Spray Voltage 4500 V, Curtain Gas 30 psi, Nebulizer Gas 
30 psi, Heating Gas 40 psi, and Source Temperature 550 oC. 
 
2.2.5 Quantification 
Quantification of free SA in plasma was performed using 13C3-SA as calibration 
standard and KDN as IS. SA concentration in unknown sample was calculated according 
to the equation: C= Ci × 0.990, where C was the SA concentration; Ci was the value for 
the sample obtained directly from the calibration curve, which was constructed using 
Multiquan by assaying 13C3-SA spiked plasma calibrators at seven concentrations in the 
range of 20.0 - 2.00 × 104 ng/mL; 0.990 was the conversion factor, calculated by the ratio 
of molecular weight of SA to 13C3-SA. 
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2.3 Results and discussion 
2.3.1 Derivatization of SAs 
SAs exist in either free form or conjugated form of glycoproteins and glycolipids. 
Among all the SA species, Neu5Ac is the most abundant in human. In this study, we aimed 
to develop a sensitive and accurate method for quantification of free Neu5Ac in human 
plasma. DMB-based quinoxalinone derivatization has been widely used for SA 
quantification [15, 16, 18-20, 22, 31], in which DMB is specialized for α-keto carboxylic 
acid with good florescent and MS response. However, DMB is not only instable due to 
light and oxygen sensitivity, but also very expensive. In our experiments, we observed that 
DMB changed color during a short weighing process, and the chromatographic peak area 
of the DMB-SA varied day to day. Therefore, fresh DMB solution needs to be prepared for 
each assay, which is very time consuming and often causes analytical variations due to the 
high instability of this reagent. In order to overcome this limitation, we have examined 
other commercially available compounds having the similar 1,2-diamino-benzene structure 
as DMB for SA derivitization and LC-MS/MS analysis (Figure 6). First, commercial free 
SA (Neu5Ac) was used for derivitization and optimization study. We found that SA 
derivatization with DAT afforded a similar MS intensity as DMB, while 4-bromo-1,2-
diaminobenzene, and 4-nitro-O-phenylenediamine were about 1/10 and 1/100 of DMB 
response, respectively. Therefore, we chose DAT for further optimization of the 
derivatization conditions including the concentration, reaction time and temperature. As a 
result, DAT concentration higher than 5 mM gave the maximum and constant MS response, 
and 80 oC gave the most intense MS peak comparing to 50 oC and 37 oC reaction 
temperature. In addition, the highest MS response was achieved after 30 min, and then 
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began to decrease after 80 min. Based on these results, the derivatization of SA was set at 
80 oC for 40 min with 10 mM of DAT.  
For comparing the stability and reproducibility of DAT and DMB derivatives, the 
two freshly prepared reagents were reacted with standard SA solutions at 40 ng/mL 
individually on seven consecutive days in our newly developed procedure above and using 
the literature condition [16], in which DMB dihydrochloride (7.0 mM) was dissolved in 
1.4 M acetic acid containing 18 mM sodium hydrosulfite and 0.75 M 2-mercaptoethanol 
and then the reaction was conducted at 50 oC for 2.5 h in dark, respectively. The 
derivatization products of each day were stored at -20 oC in dark, and analyzed at the end 
of the seventh day all together in one batch using LC-MS/MS. DMB-IS and DAT-IS 
samples were prepared on the seventh day, and spiked into each of the corresponding SA 
derivatives before LC-MS/MS analysis. As a result (Table III), DMB-SA showed a relative 
error from -37% to 88%, while DAT-SA had only -6% to 9% error. Since both reagents 
and their products were stabilized by sodium hydrosulfite and 2-mercaptoethanol, the 
larger variation of DMB-SA may be due to its high instability with light and oxygen, which 
makes it difficult to handle in a repeatable manner. Furthermore, another advantage of DAT 
was the low price, thousands of times cheaper than DMB. In fact, the high cost of DMB is 
a problem considering that its reagent solution needs to be prepared freshly each time.  
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TABLE III:  Reproducibility of DMB and DAT derivatization (n = 3) 
  Spiked conc. 1st day 2ed day 3rd day 4th day 5th day 6th day 7th day 
DMB-SA (ng/mL) 40.0 50.3  75.2  25.3  46.3  32.0  57.6  40.0  
RE %   26  88  -37  16  -20  44  0  
DAT-SA (ng/mL) 40.0 37.7  42.8  43.6  39.1  38.7  40.7  40.0  
RE %  -6  7  9  -2  -3  2  0  
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2.3.2 Isotope-labeled standard calibration (ILSC) 
According to the FDA guidelines for validation of bioanalytical methods, the 
calibrators and QCs for analysis should be prepared using the same types of matrices as 
samples to be measured [34]. It has been strongly recommended to use matrix-matched 
calibration for quantification assays employing LC-MS or LC-MS/MS due to such a matrix 
effect that some of the matrix components could suppress or enhance the mass 
spectrometry signals of the analytes or IS [32]. An HPLC-ESI-MS/MS method developed 
for the quantification of free SA in urine employed creatinine-adjusted urine as blank 
matrix for calibration preparation, which had a limit of detection of 927 ng/mL [24]. In 
order to achieve highly sensitive and accurate quantification, we used 13C3-SA as a 
surrogate standard to generate calibration curves and QC samples. Since 13C3-SA possesses 
the same chemical structure and properties as SA, and they have identical stability, 
derivatization efficiency, chromatographic retention, and MS response and fragmentation 
pattern, the specific and sensitive detection of them could be obtained by mass 
spectrometry in MRM mode upon their difference in m/z values. 
 
2.3.3 Optimization of LC-MS/MS conditions 
Chromatographic conditions were optimized to obtain higher specificity, 
sensitivity, and shorter analysis time. Various mobile phases including different 
percentages of methanol in water and acetonitrile in water with or without additives were 
evaluated, and 20% methanol at 0.3 ml/min provided the optimal results. It was found that 
the LC-MS/MS signal from 13C3-SA was at least two times higher with methanol-water as 
mobile phase than acetonitrile-water. Addition of formic acid or ammonium acetate into 
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the mobile phase substantially reduced the peak intensity. Under this selected 
chromatographic conditions, the retention times for SA, 13C3-SA and IS were 3.6 min, 3.6 
min, and 2.4 min, respectively. The total run time was 4.2 min, which was the shortest 
analysis time for quantification of free SA reported so far [11-31].   
The product ion scan spectra of [M+H]+ precursors from the derivatized SA, 13C3-
SA and IS are illustrated in Figure 7 A-C; the proposed fragmentation pathway for SA is 
shown in Figure 8. The calibration standard, 13C3-SA, had three relatively abundant 
fragments with m/z 256, 286, and 381. However, m/z 256 was found to have the highest 
signal to noise ratio (S/N) at LLOQ concentration than the other two fragment ions. After 
optimization and evaluation, we selected transitions of m/z 396 → 253 for SA, 399 → 256 
for 13C3-SA, and 355 → 175 for IS as the MRM channels for quantification. The transitions 
of 396 → 283 for SA and 399 → 286 for 13C3-SA were also monitored during LC-MS/MS 
analysis for quality assurance. 
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Figure 7: Product ion spectra of [M+H]+ precursors. (A) DAT-SA, (B) DAT-13C3-SA, 
(C) DAT-IS. 
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Figure 8: Proposed fragmentation pathway of [DAT-SA+H] +.  
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2.3.4 Free SA extraction from plasma 
There are both free SA and conjugated SA in human plasma, all together called 
total SA, and free SA accounts a small portion of total SA. Therefore, it is critical to 
effectively extract free SA from the plasma and separate the conjugated forms from the 
extractants. In this study, three different extraction methods were examined, including PPT 
with acetonitrile and methanol, and dialysis with 3 kD centrifugal filter (Amicon® Ultra, 
catalog number R1NA37692). Methanol and acetonitrile were often used for PPT with 
human fluid to obtain free SA [28,29]. In our study, free SA peaks in plasma samples after 
methanol-PPT were about 30 times higher than those after acetonitrile-PPT (Table IV). 
This may be attributed to the incomplete removal of conjugated SA from plasma. To test 
this hypothesis, the supernatants of both methanol- and acetonitrile-PPT samples were 
dried with nitrogen at 37 oC, and the residues were reconstituted into the same volume of 
water. Then 20 μL of each sample was subjected to 15% SDS-PAGE analysis. As shown 
in Figure 9, trace proteins exist in methanol-PPT samples, while no protein bands were 
observed in acetonitrile-PPT samples, indicating a complete remove of proteins. Therefore, 
acetonitrile-PPT was used to remove the conjugated SA and obtain the free SA from 
plasma in our study. 
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TABLE IV: SA peak areas from different sample preparations (n = 3).  
 Dialysis Methanol-PPT  Acetonitrile-PPT Non-extraction 
Area (counts) (6.31 ± 0.42) × 105 (1.69 ± 0.13) × 107 (6.02 ± 0.24) × 105 (2.54 ± 0.21) × 108 
 
 
Figure 9: SDS-PAGE chromatograms of plasma and its PPT samples: (A) Protein ladder, (B) human plasma, (C) plasma samples 
precipitated with methanol, (D) plasma samples precipitated with acetonitrile. 
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2.3.5 Method validation 
2.3.5.1 Linearity of calibration 
Calibration curves were constructed using seven calibrators prepared from pooled 
plasma spiked with 13C3-SA at concentration range of 20.0 - 2.00 × 104 ng/mL and IS at 
3.00 × 103 ng/mL. A typical equation obtained from weighted (1/x) linear regression was 
y = 9.27 × 10-4 x - 3.13 × 10-4, where y was the peak area ratio of 13C3- SA to IS, and x 
was the concentration of 13C3- SA in spiked plasma. The correlation coefficient (r) was at 
least 0.999, indicating that the calibration was highly linear within the concentration range. 
 
2.3.5.2 Specificity, sensitivity, and LLOQ 
The specificity and sensitivity were evaluated by analyzing LLOQ samples 
prepared from six individual lots of plasma and the blanks (no 13C3-SA or IS) from the 
same lots of plasma. As shown in Figure 10, no significant interference was observed in 
the retention time windows of 13C3-SA and IS. The coefficient of variation (CV) and 
relative error (RE) for measurement of LLOQ samples were 6% and -1%, respectively, 
which indicated that this assay was sensitive enough to quantify SA at 20 ng/mL. 
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Figure 10: Representative MRM chromatograms of native/labeled SA and IS. (A) A 
pooled blank plasma sample, (B) a pooled plasma sample spiked with 13C3-SA at the LLOQ 
of 20.0 ng/mL and IS, (C) a plasma sample from a patient spiked with IS. 
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2.3.5.3 Extraction recovery and matrix effect 
The extraction recovery of free SA from plasma using acetonitrile-PPT was 
determined by comparing chromatographic peak areas from two sets of plasma samples. 
The first set was spiked with 13C3-SA at three QC levels and IS before PPT, and the second 
set was spiked at the corresponding concentrations after PPT. The absolute extraction 
recovery of 13C3-SA was over 70%, and the IS-normalized recovery was nearly 100%. To 
evaluate the matrix effect, the peak areas obtained from the second set of extraction 
recovery samples were compared with those of 13C3-SA and IS prepared in water at 
equivalent concentrations. Both the absolute and IS-normalized matrix effect were close to 
100%, which meant the matrix effect was negligible in this study. 
 
2.3.5.4 Precision and accuracy 
The intra-assay and inter-assay precision and accuracy were studied by determining 
the QC samples at three concentrations in five replicates, and the results are listed in Table 
V. The CV was within 5% and the RE was in the range of -5 to 5%, which well fulfilled 
the FDA criteria for bioanalysis [34].   
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TABLE V: Intra- and inter-assay precision and accuracy for measurement of spiked 13C3-SA in plasma (n=5) 
QC 
Spiked conc. 
(ng/mL) 
Intra-assay Inter-assay 
Mean ± SD 
(ng/mL) 
Precision 
(CV %) a 
Accuracy 
(RE %) b 
Mean ± SD 
(ng/mL) 
Precision 
(CV %) 
Accuracy 
(RE %) 
Low 40.0 39.9 ± 1.4 3 -1 38.1 ± 1.8 5 -5 
Mid 800 839 ± 17 2 5 811 ± 29 4 1 
High 1.60 × 104 (1.67 ± 0.03) × 104 2 4 (1.65 ± 0.06) × 104 4 3 
a CV % = (SD/Mean) × 100% 
b RE % = [(Mean – Spiked)/Spiked] × 100% 
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2.3.5.5 Stability 
The stability of SA-DAT derivatives in human plasma was assessed by analyzing 
five replicates of low and high QC samples undergoing different storage conditions pre and 
post sample preparations. As shown in Table VI, there was essentially no change with 13C3-
SA in the QC samples kept at -80 oC for two weeks, or room temperature (RT) for 8 hours. 
It was also stable in the autosampler at 4 oC for 10 hours post sample preparation. 
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TABLE VI:  Stability of 13C3-SA in plasma pre and post sample preparation (n = 5) 
Storage condition QC Spiked conc. (ng/mL) 
Mean ± SD  
(ng/mL) 
Stability (Recovery %) a 
2 weeks at -80 oC Low  40.0 41.1 ± 2.8 103  High 1.60 × 104 (1.60 ± 0.06) × 104 100 
3 freeze (-80 oC)-thaw (RT) cycles 
Low  40.0 42.3 ± 1.5 106  
High 1.60 × 104 (1.70 ± 0.06) ×104 106 
8 h at RT Low  40.0 39.8 ± 1.9  100  High 1.60 × 104 (1.68 ± 0.06) × 104 105 
10 h at 4 oC post preparation 
Low  40.0 42.6 ± 1.3 107  
High 1.60 × 104 (1.75 ± 0.04) × 104 110 
a Recovery % = Mean/Spiked × 100% 
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2.3.6 Assay application 
This validated method was applied to determine free SA in plasma samples from 
30 patients and 6 normal people. The free SA concentration in patient samples ranged from 
419 to 862 ng/mL with an average of 651 ng/mL, while in normal people, the free SA 
concentration ranged from 280 to 354 ng/mL with an average 323 ng/mL (Figure 11). To 
our best knowledge, this is the first study to quantify free SA in human plasma using LC-
MS/MS. In order to make statistical assumption, measurement of a large number of 
samples needs to be carried out in the future. 
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Figure 11: Free SA in plasma samples from 30 patients and 6 healthy people. 
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2.4 Conclusion 
We developed a LC-MS/MS method with isotope-labeled standard calibration for 
sensitive quantification of free SA in human plasma, in which free SA, 13C3-SA as 
calibration standard, and KDN as IS were derivatized with a stable and inexpensive DAT. 
Briefly, plasma samples were first mixed with acetonitrile to precipitate proteins and 
separate free SA from conjugated SA. Then the free SA, 13C3-SA, and IS were derivatized 
with DAT. The derivatives were injected onto a Phenomenex Kinetex C18 column for 
separation using a mixture of water-methanol (80/20, v/v) as the mobile phase at an 
isocratic flow of 0.3 mL/min. The detection was performed on an AB Sciex Qtrap 5500 
mass spectrometer with positive ESI employing multiple reaction monitoring (MRM) 
mode. Overall, we have demonstrated a robust derivatization of SA with DAT, which is 
cost-effective and provides a stable product of SA with high MS response. We have 
achieved a LLOQ of 20 ng/mL and a total run time of 4.2 min, which is the most sensitive 
and fast measurement for free SA in biomatrices. This assay was validated for linearity, 
precision and accuracy, and stability following the FDA guidance for bioanalytical method 
validation. The method was successfully applied to quantification of free SA in human 
plasma and is expected to be applied for accurate quantification of SA for both biological 
research and clinical applications. 
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CHAPTER III 
GLOBALLY PROFILING SIALYLATION STATUS OF 
MACROPHAGES UPON STATIN TREATMENT 
 
 
3.1 Introduction 
SAs ubiquitously distribute on the cell surfaces and locate on the outermost position 
of the glycan structures in a variety of glycoconjugates [1-3]. This particularly spatial 
orientation and great abundance endows SAs with important functions in a wide range of 
physiological and pathological processes, such as immunological process, cell adhesion 
and infection [3, 4]. SAs expressed on immune cells are closely related to their activities. 
An early study found that macrophages form rosettes with normal sheep erythrocytes but 
not the one after sialidase pretreatment [5]. Also, guinea pig peritoneal macrophages 
pretreated with sialidase bound more 125I-IgG than non-treated cells [6]. Further, sialidase 
treatment can substantially enhance the capacity of resting B cells to stimulate the 
proliferation of allogeneic and antigen specific syngeneic T cells [7-9]. All these studies 
reveal a fact that cell surface SAs on immune cells are involved in a diverse regulation of 
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immune cell interactions and play important roles related to both physiological and 
pathological processes. 
So far, a number of studies have been performed on the SA binding proteins in the 
immune system. The SAs recognizing proteins are categorized to the family of siglecs, 
which represents SAs recognizing Ig superfamily lectins. The founding members of the   
siglec family include sialoadhesin (siglec-1), a macrophage adhesion molecule [10-12]; 
CD22 (siglec-2), a B-cell inhibitory receptor [13]; CD33 (siglec-3), a marker of myeloid 
cells [14]; and myelin associated glycoprotein (MAG or siglec-4), expressed by 
oligodendrocytes and Schwann cells in the nervous system [15]. Despite the extensive 
studies on the SAs binding proteins in the immune system, the SAs profile of immune cells 
themselves was largely overlooked for decades. In particular, the sialylation status related 
to the linkages and the amount of SAs on the immune cell surface is less known so far.  
It was reported that cell surface sialylation pattern changes during apoptosis in 
several cell types, including colon carcinomas and thymocytes [16, 17]. Also, cell surface 
sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell 
death [18]. A recent study found that decreasing of SA residues on the surface of apoptotic 
lymphocytes was recognized as an “Eat-Me” signal [19]. In addition, it was reported that 
ST6Gal-I regulates macrophage apoptosis via α-2,6 sialylation of the TNFR1 death 
receptor [20].  
Statin drugs, as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, are widely used in the treatment of hypercholesterolemia for more than a 
decade. In addition to their lipid-lowering effect, convincing evidence demonstrated that 
statins have a wide effect on macrophages. For example, statins were found to reduce the 
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cell numbers of macrophages in vivo and in vitro [21-23], and one mechanism could be 
attributed to its apoptosis induction effect on macrophages at even low dosages [22, 23]. 
Moreover, the immunomodulatory roles of statin have been studied in macrophages on the 
cytokine and corresponding protein levels, such as inhibiting inducible nitric oxide 
synthase [24, 25], augmenting LPS-induced proinflammatory responses [26], and inducing 
Th2 cytokines secretion while suppressing Th1 cytokines production [27]. Although detail 
mechanisms have been elucidated in each study, most of these pleiotropic effects are 
mediated by the inhibition of the synthesis of isoprenoid intermediates such as 
farnesylpyrophosphate and geranylgeranylpyrophosphate, which are essential for many 
cellular functions like differentiation and proliferation [28].  
In this study, we systematically investigated the sialylation status of macrophages 
in the normal culture condition and after atorvastation treatment. In particular, we globally 
profiled SAs linkages and levels of respective SA forms on the cell surface by confocal 
microscopy and flow cytometry with SA-specific lectins SNA and MAA. Further, free, 
conjugated, and total SAs in the cell culture medium and total SAs in the cells were 
quantified in both normal and statin-treated conditions by a newly developed LC-MS/MS 
method. The combination of confocal microscopy, flow cytometry, and LC-MS/MS 
provides the first time of global investigation of the cellular sialylation status of 
macrophages in the entire cell culture system, which will contribute to a better 
understanding of the physiological and pathological roles of SAs in macrophages and in 
the immune system as well. 
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3.2 Materials and methods 
3.2.1 Materials 
FITC labeled MAA lectin was purchased from bioWORLD (Dublin, OH, USA). 
FITC labeled SNA lectin was provided by Vector Laboratories (Burlingame, CA, USA). 
Alexa Fluor 488 labeled Annexin V, APC labeled Annexin V, and ProLong Gold Antifade 
Mountant were obtained from Life Technologies (Grand Island, NY, USA). Atorvastatin 
was purchased from A Chem Tek Inc. (Worcester, MA, USA). N-acetyl-D-neuraminic acid 
(SA, 98%) was supplied by Rose Scientific Ltd. (Edmonton AB, Canada). N-acetyl-D-
neuraminic acid-1,2,3-13C3 (13C3-SA, 99%), 4',6-diamidino-2-phenylindole (DAPI), 
propidium iodide (PI), RIPA buffer, protease inhibitor cocktail, rabbit anti-ST6Gal-I 
antibody, rabbit anti-ST6GalNAc-II antibody, rabbit anti-ST6GalNAc-VI antibody, and 
goat anti-rabbit IgG-peroxidase antibody were purchased from Sigma-Aldrich Inc. (St. 
Louis, MO, USA). Acetonitrile (HPLC grade), paraformaldehyde (PFA, 16% w/v), and 
acetic acid (ACS grade) were obtained from Fisher Scientific (Hanover park, IL, USA). 
 
3.2.2 Apparatus 
Flow cytometry was performed on a FACSCanto Ⅱ system consisting of a blue 
and a red laser, operated through BD FACSDiva software (BD Bioscience, Mountain 
View, CA, USA). Images were acquired at a 60 × magnification using a Nikon A1Rsi 
confocal microscope, and data analysis was performed using NIS-Elements software 
(Nikon Instruments Inc., Melville, NY, USA). LC-MS/MS quantification was carried out 
by a Nexera liquid chromatography system (Shimadzu, Columbia, MD, USA) interfaced 
to a Qtrap 5500 mass spectrometer equipped with eletrospray ionization source (AB 
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SCIEX, Framingham, MA, USA), and the data acquisition and processing were conducted 
using Analysis 1.6.1 software. 
 
3.2.3 Cell culture and stimulation 
Raw 264.7 cells, obtained from American Type Culture Collection, were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM, Cleveland Clinic Core Facility, 
Cleveland, OH, USA) supplemented with 10% fetal bovine serum (FBS, Atlanta 
Biologicals, Flowery branch, GA, USA) and 1% penicillin/streptomycin (Cleveland Clinic 
Core Facility, Cleveland, OH, USA) in a humidified atmosphere containing 5% CO2 at 37 
oC. In order to quantify free SAs, FBS was removed from culture medium before adding 
drug. For atorvastatin simulation, cells were seeded in 6-well plates for overnight, followed 
by atorvastatin treatment at different concentrations and incubation times. The media 
without FBS were collected and centrifuged at 15,000 g for 5 min. The supernatants were 
stored at -20 oC until use. Cells were analyzed by flow cytometry, confocal microscopy, or 
LC-MS/MS. 
 
3.2.4 Flow cytometric analysis 
For determination of cell surface SA, cells were treated with atorvastatin (or 
vehicle) for 24h. The cells were harvested and washed 3 times with cold phosphate buffered 
saline (PBS), and then suspended in 50 μL MAA (10 μg/mL) or SNA (20 μg/mL), and 5 
μL PI (1000 μg/mL). After incubation for 30 min at room temperature, cells were washed 
with cold PBS for 3 times and re-suspended in the same buffer for flow analysis. A 
minimum of 20,000 cells were measured each time.  
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Cell apoptosis study was performed by staining cells with Annexin V and PI using 
the dead cell apoptosis kit (Life technologies, Grand Island, NY, USA). Briefly, cells 
treated with or without 20 μM atorvastatin for 14, 24, and 38 h were collected and washed 
3 times with cold PBS, and then resuspended in 100 μL of 1 × binding buffer provided by 
the manufacturer. Annexin V (5 μL) and PI (1 μL) were added to the cell suspension and 
incubated at room temperature for 15 min. After incubation, 400 μL of 1 × binding buffer 
was added to each vial and cells were analyzed immediately with flow cytometry. 
 
3.2.5 Confocal microscopy 
Cells were seeded on cover slip in 6-well plate for overnight, and then treated with 
20 μM atorvastatin (or vehicle) for 24 h. After incubation, cells on cover slip were washed 
for 3 times with cold PBS, and fixed with 4% PFA for 10 min. Excess PFA was removed 
by another 3 times wash with cold PBS. Then cells were stained with MAA-FITC (10 
μg/mL) or SNA-FITC (20 μg/mL) for 30 min, followed by 1 min DAPI stain. Unbound 
lectin was washed off with cold PBS and cover glasses were mounted on ProLong Gold 
Antifade reagent. 
 
3.2.6 LC-MS/MS analysis 
SA and IS were separated by a Primesep D column (2.1 × 100mm, 5 μm; SIELC 
Technologies, Prospect Heights, IL, USA) with a binary linear gradient elution, in which 
phase A was deionized water containing 10 mM ammonium formate and 0.1% formic acid, 
and phase B was a mixture of 90% acetonitrile, 10% water, 3 mM ammonium formate, and 
0.04% formic acid. The gradient program started at 10% B and maintained for 1 min, and 
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then changed linearly to 100% B in 3 min and maintained for 2 min. In order to equilibrate 
the column, the gradient sharply dropped to 10% B in 0.1 min and kept for 2.9 min. The 
total run time was 9 min for each sample. The MS detection was carried out in negative 
electrospray ionization and MRM mode. The quantitative MRM transitions were set at m/z 
308 → 87 for SA, and 311 → 90 for IS. The quality assurance MRM channel for SA was 
set at m/z 308 → 170. 
 
3.2.6.1 Method validation sample preparation 
SA calibration standards were prepared in DMEM at concentrations of 2.00, 6.00, 
20.0, 60.0, 200, 600, 2.00×103 ng/mL. The QC samples were prepared in the same manner 
at low, mid and high concentrations of 4.00, 100, and 1.60×103 ng/mL. IS was prepared in 
DMEM at the concentration of 2.00×103 ng/mL. For the sample preparation, 5 μL IS was 
mixed together with 95 μL calibration standards or QC samples, and 5 μL of the mixture 
was subjected to the LC-MS/MS analysis. 
 
3.2.6.2 Cell culture sample preparation 
Free SA in the medium was quantified by spiking 95 μL of culture medium with 5 
μL of IS, and then 5 μL of the mixture was injection to LC-MS/MS system. In order to 
determine total SA in culture medium, the sample was first hydrolyzed with 2 M acetic 
acid (1:1) at 80 oC for 90 min, and then 5 μL of the IS was added to 95 μL of the lysate 
before analysis. For quantification of total SA of the cell, the sample at a density of 1×106 
cells/mL was untrosonicated to obtain homogeneous mixture. Then follow the procedure 
of total SA quantification in culture medium. 
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3.2.7 Western blot 
Cells were washed twice with ice-cold PBS and lysed with RIPA buffer on ice for 
5 min. The cell lysates were collected and clarified by centrifugation at 15,000 g at 4 oC 
for 10 min. Protein concentrations were measured by the Bradford method using a protein 
assay kit (Bio-Rad, Hercules, CA, USA). Proteins (30 μg/sample) were fractionated on 
SDS-15% polyacrylamide gels and transferred to polyvinylidene difluoride membrane. 
The membranes were blocked with 5% nonfat milk in Tri-buffered saline containing 0.05% 
Tween 20 (TBS-T) for 1 h at room temperature, and then probed with primary antibodies 
in TBS-T buffer with 5% nonfat milk at 4 oC overnight. The membranes were washed 3 
times with TBS-T buffer, followed by incubation with secondary antibody for 1 h at room 
temperature. Antibody detection was accomplished by using the ECL Prime kit (Pierce) 
with the LI-COR Odyssey Fc imaging system. 
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3.3 Results 
3.3.1 Cell surface SAs analyzed by confocal microscopy and flow cytometry 
SAs are commonly found α-2,3 and α-2,6 linked to galactose residue on the cell 
surface [29]. In our study, we first performed confocal microscopy and flow cytometry 
analysis to distinctively measure SAs with different linkages on the macrophage surfaces 
by using MAA-FITC and SNA-FITC, which specifically bind to α-2,3 and α-2,6 linked 
SAs, respectively. From the confocal microscopy study, MAA-FITC showed very strong 
binding compared to SNA-FITC on the cell surface of macrophages cultured under the 
normal condition (Figure 12A). After cells were treated with atorvastatin for 24 h, MAA-
FITC binding remained unchanged (Figure 12B), while SNA-FITC binding increased 
dramatically (Figure 12B). 
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Figure 12: Confocal microscopy analysis of cell surface SA. (A): Raw 264.7 cells at 
the normal culture condition were stained with MAA-FITC (10 μg/mL) and SNA-FITC 
(20 μg/mL), respectively. DAPI was used to stain nuclei. (B): Raw 264.7 cells were treated 
with 20 μM atorvastatin for 24 h followed by staining with lectins and DAPI. The scale bar 
represents 10 μm. (C): The fluorescent intensity of the confocal images was analyzed by 
ImageJ obtained from National Institutes of Health (n = 4). 
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Next, the lectin-labeled cells were analyzed by flow cytometry. The similar binding 
pattern was observed from macrophages under the normal and atorvastatin conditions. In 
particular, SNA-FITC binding for macrophages was significantly increased upon 
atorvastatin treatment (Figure 13). The dot plots indicated that approximately 80% of the 
cells were MAA positive and 10% were SNA positive in the normal condition (Figure 
13A). After 24 h atorvastatin treatment, no apparent change in MAA-FITC labeling was 
observed, but peak shift was apparently found from SNA-FITC labeled cells (Figure 13B). 
The dot plots showed the total ratio of SNA positive cells increased about 3 times as 
compared with the untreated cells. Further, the lectin stainings were performed on 
permeabilized cells, and the peak shift was found in SNA-FITC labeled cells in both 
permeabilized and non-permeabilized conditions with atorvastatin treatment, while no 
significant change in MAA-FITC labeled cells were observed. Interestingly, large peak 
shift was found in SNA-FITC labeled cells with permeabilization independent on 
atorvastatin treatment (Figure 14). These results indicate that 2,6 linked SA increased both 
on the cell surfaces and inside the cells. 
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Figure 13: Determination of cell surface SAs by flow cytometry. (A): Raw 264.7 cells 
at normal condition were stained with MAA-FITC (10 μg/mL) and SNA-FITC (20 μg/mL), 
respectively. PI staining was used to distinguish living cells and dead cells. (B): Raw 264.7 
cells were treated with 20 μM atorvastatin for 24 h then stained with lectins and PI. Data 
is a representative of at least three independent experiments. 
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Figure 14: Comparison of SAs level after cell permeabilization. Atorvastatin +: Cells 
were treated with 20 μM atorvastatin for 24 h. Atorvastatin -: Cells were incubated with 
vehicle for 24 h. Permeabilization +: Cells were fixed with 4% PFA, followed by 
permeabilization with 0.2% triton X-100, and then labeled with lectins. Permeabilization -
: Cells were fixed with 4% PFA, and then labeled with lectins. (A):  Raw 264.7 cells at 
different conditions were labeled with MAA-FITC (10 μg/mL). (B):  Raw 264.7 cells at 
different conditions were labeled with SNA-FITC (20 μg/mL).  
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3.3.2 Comparison of SNA and Annexin V staining 
It is known that statins stimulate apoptotic cell death in several types of immune 
cells, such as macrophages [22, 23]. Annexin V specifically binds to membrane 
phosphatidylserine and has been widely used for early apoptosis detection [30, 31]. In our 
study above, a significant SNA-FITC staining increase was observed for atorvastatin 
treated cells compared with MAA-FITC staining (Figure 12B and 13B). Therefore, we 
compared the SNA labeling and Annexin V labeling of the cells treated with 20 μM 
atorvastatin for 14, 24, and 38 h, respectively. As shown in Figure 15A, both SNA and 
Annexin V positive cells increased dramatically with the incubation time prolonged. 
Briefly, in the control sample (0 h), the SNA positive cell ratio was only 9.4%, which 
included both PI positive and negative cells, while the SNA positive cells increased to 
23.5%, 33.6% and 41.3% when the cells were incubated with atorvastatin for 14, 24 and 
38 h, respectively. Meanwhile, Annexin V positive cells increased in the same time-
dependent manner as SNA labeling. However, the change scale of Annexin V labeling was 
smaller compared with SNA labeling. These results are further supported by the SNA and 
Annexin V co-stainings of the cells (Figure 15 B). All these results indicated that α-2,6 
linked SAs were highly expressed on the surface of cells undergoing apoptosis and thus 
may be used as a marker for apoptosis detection as well. Further study to prove the 
correlation of macrophage apoptosis and α-2,6 linked SAs status is much deserved. 
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Figure 15: Comparison of SNA and Annexin V labeling of Raw 264.7 cells after cells 
incubated with atorvastatin. (A): Cells were treated with or without atorvastatin (20 μM) 
for 14, 24 and 38 h, and then labeled with SNA or Annexin V. Both PI positive and negative 
cells are included here. Values represent means and standard deviations from three 
independent experiments (n=3). (B): Cells were treated with atorvastatin (or vehicle) for 
24h, and then co-stained with SNA-FITC and Annexin V-APC. 
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3.3.3 LC-MS/MS quantification of SAs in the culture media and cell lysates 
3.3.3.1 Method validation 
In this study, we developed a new LC-MS/MS method to quantitatively examine 
the free SAs and conjugated SAs levels in the cell culture media, and the total SAs in the 
cell lysates upon cell treated with atorvastatin. The mass spectra for both SA and 13C3-SA 
(internal standard, IS) were obtained in negative electrospray ionization (Figure 16). The 
MS detection was carried out in negative electrospray ionization and multiple reaction 
monitoring (MRM) mode. The representative chromatograms for the LLOQ sample and a 
sample obtained from cells are shown in Figure 17. The calibration range was obtained 
from 2.00 to 2.00 × 103 ng/mL and the LLOQ was 2.00 ng/mL. Importantly, the large 
calibration range and low LLOQ facilitate the determination of small amount of free SAs 
in the cell culture medium and total SAs in the cell lysate. This method was validated for 
matrix effect (Table VII), precision and accuracy (Table VIII), and stability (Table IX). 
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Figure 16: The mass spectra of SA and 13C3-SA (IS). SA or 13C3-SA standard solution 
at a concentration of 100 ng/mL in water was infused into mass spectrometer at a speed of 
10 μL/min. After ionization and fragmentation, the spectra were obtained from a product 
ion scan mode from m/z 50 to m/z 350. The fragment ions of m/z 87 for SA and m/z 90 for 
13C3-SA were selected for quantification. Fragment of m/z 170 for SA was used for quality 
assurance.  
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Figure 17: Representative MRM chromatograms of SA and 13C3-SA. (A) a culture free 
DMEM medium sample, (B) a culture free DMEM medium sample spiked with SA at the 
LLOQ of 2.0 ng/mL and 13C3-SA at 100 ng/mL, (C) a cell lysate sample from a cell density 
of 1×106 cells/mL spiked with 13C3-SA at 100 ng/mL. 
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TABLE VII: Matrix effect of SA spiked in cell culture medium (n=4) 
Spiked SA (ng/mL) Peak Area (counts) Matrix Effect a SA in Medium SA in Water 
4.00 1.72 × 104 1.72 × 104 100% 
100 4.07 × 105 4.08 × 105 100% 
1.60 × 103 6.92 × 106 6.59 × 106 105% 
a Matrix Effect = mean peak area of SA in culture medium / mean peak area ratio of SA in water 
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TABLE VIII: Intra- and inter-assay precision and accuracy for measurement of spiked SA in cell culture medium (n=5) 
Spiked SA 
(ng/mL) 
Intra-assay Inter-assay 
Mean ± SD 
(ng/mL) 
Precision 
(CV %) a 
Accuracy 
(RE %) b 
Mean ± SD 
(ng/mL) 
Precision 
(CV %) 
Accuracy 
(RE %) 
4.00 3.90 ± 0.08 2 -2 4.00 ± 0.08 2 0 
100 97.9 ± 2.8 3 -2 96.3 ± 2.2 2 -4 
1.60 × 103 (1.65 ± 0.04) × 103 2 3 (1.61 ± 0.02) × 103 1 1 
a CV % = (SD/Mean) × 100% 
b RE % = [(Mean - Spiked)/Spiked] × 100 
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TABLE IX: Stability of SA in cell culture medium (n = 5) 
Storage Condition Spiked SA (ng/mL) Mean ± SD (ng/mL) Stability (Recovery % )a 
8 h at RTb 4.00 3.95 ± 0.09 98.8 1.60 × 103 (1.60 ± 0.01) × 103 100 
24 h at 4 oC 4.00 3.96 ± 0.13 99.1 1.60 × 103 (1.67 ± 0.06) × 103 104 
3 freeze-thaw (RT) cycles 
4.00 4.07 ± 0.20 102 
1.60 × 103 (1.60 ± 0.03) × 103 100 
72h at 37 oC 4.00 4.04 ± 0.17 101 1.60 × 103 (1.60 ± 0.04) × 103 100 
a Recovery % = Mean/Spiked × 100% 
b RT: room temperature 
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3.3.3.2 SAs concentration in cell culture samples 
The validated method was successfully used for quantifying the free SAs and 
conjugated SAs in the cell culture media, and the total SAs in the cell lysates, which would 
indicate SAs releasing and synthesis fact related to cell function alteration (Figure 18). 
First, the concentrations of free SAs in the cell culture media under the normal culture 
condition and incubation with atorvastatin for 24 h were measured by LC-MS/MS. As a 
result, free SAs in the normal culture condition were 6.31 ± 0.45 ng/mL and no apparent 
change was observed after atorvastatin treatment. Meanwhile, the total SAs and conjugated 
SAs in the cell culture media were 73.2 ± 3.3 ng/mL and 66.9 ± 3.6 ng/mL under the normal 
condition and slightly increased to 80.9 ± 7.1 ng/mL and 74.3 ± 7.0 ng/mL, respectively, 
after incubation with 20 μM atorvastatin. Next, the total cellular SAs, including on the cell 
surfaces and inside the cells were measured by LC-MS/MS after releasing SAs from the 
cell lysates. As a result, the cellular SAs concentration was 369 ± 29 ng/mL at a density of 
1×106 cells/mL under the normal culture condition, while it increased to 567 ± 25, 775 ± 
32 and 1080 ± 50 ng/mL corresponding to 5, 10 and 20 μM of atorvastatin used, 
respectively. 
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Figure 18: SAs concentrations in the cell culture system. Cells were treated with 
vehicle (0 μM) or atorvastatin at 5, 10, and 20 μM for 24 h. Then free SAs in the medium 
were quantified by LC-MS/MS directly. The medium was hydrolyzed with acetic acid 
followed by LC-MS/MS analysis to determine the total SAs. Conjugated SAs in the 
medium were calculated by subtracting the free form from total SAs. In order to quantify 
total SAs of the cell, cells were first ultrasonicated to obtain homogeneous mixture, 
followed by acid hydrolysis and LC-MS/MS analysis. MF, medium free SA; MC, medium 
conjugated SA; MT, medium total SA; CT, cell total SA. The results were repeated in at 
least three independent experiments.  Data is a representative from one experiment with 
three samples (n=3). 
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3.3.4 Western blot analysis of selected α-2,6 sialyltransferase level 
The LC-MS/MS results of increased cellular SAs may be in accordance with the 
increase of α-2,6 linked SAs on the cell surface after atorvastatin treatment as observed by 
flow cytometry and confocal microscopy above. Therefore, we further performed western 
blot analysis of the cellular α-2,6 sialyltransferases in normal and statin conditions. These 
sialyltransferases are grouped into two families according to the carbohydrate linkages they 
synthesize, including ST6Gal I and II, and ST6GalNAc I-VI [32]. ST6Gal-I for N-glycan, 
ST6GalNAc-II for O-glycan, and ST6GalNAc-VI for glycolipids have been investigated 
on immune cells [32-34]. As shown in Figure 19, ST6GalNAc-II was found highly 
increased, ST6GalNAc-VI no apparent change, while ST6Gal-I decreased upon 
atorvastatin treatment (with 20 μM for 24 h). Therefore, the elevation of ST6GalNAc-II 
may contribute to the increased cellular SAs and α-2,6 linked SAs on the cell surface after 
atorvastatin treatment. There may be other sialyltransferases related to the increase of α-
2,6 linked SAs as well, which deserve a further study in future. 
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Figure 19: Western blot analysis of Raw 264.7 cells sialyltransferases upon 
atorvastatin treatment. Raw cells were incubated with 20 μM atorvastatin (or vehicle) for 
24 h, and the ST6Gal-I, ST6GalNAc-II and ST6GalNAc-VI were determined by western 
blot analysis using rabbit anti-ST6Gal-I antibody, rabbit anti-ST6GalNAc-II antibody, and 
rabbit anti-ST6GalNAc-VI antibody, respectively. 
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3.4 Discussion 
Macrophages play very important roles in the immune system related to both 
physiological and pathological pathways. SAs terminate most glycans on the cell surface 
and are involved in variety of physiological and pathological activities of immune cells. In 
this study, we used Raw 264.7 macrophages to comprehensively profile the sialylation 
status in the cell culture system including cell surface SAs levels and their linkages, 
secreted free, conjugated and total SAs in the culture medium and total SAs in the cells as 
well. First, cell surface SAs were determined by confocal microscopy and flow cytometry 
by using SNA and MAA labeling. As a result, α-2,3 linked SAs were found to be 
predominant on the Raw 264.7 macrophage surfaces, while α-2,6 linked SAs were less 
observed under the normal culture condition (Figure 12A). After cells were treated with 
atorvastatin for 24 h, α-2,3 linked SAs were unchanged, however, α-2,6 linked SAs 
increased significantly on cell surface (Figure 12B, Figure 13B). The wide distribution of 
α-2,3 linked SAs may be associated with the cell-cell interaction and signaling transduction 
under the normal condition. For example, sialoadhesin (siglec-1), a SA binding receptor 
uniquely expressed by macrophage subsets, selectively binds to only α-2,3 linked SAs [12]. 
While α-2,6 linked SAs may be associated with the cell-cell interaction and signaling 
transduction in response to external stimuli. The expression level of SAs on the cell surface 
is affected by its biosynthetic pathway. In particular, the synthetic enzyme, 
sialyltransferase, functions for adding SAs to the termini of N-linked or O-linked glycans 
on the cell surfaces [35]. In our study, western blot showed dramatically change of 
ST6GalNAc-II which may be the major contributor for the increase of cell surface α-2,6 
linked SAs.  
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It is known that glycosylation pattern, including sialylation, changes when cells 
undergo apoptosis [16, 19, 20, 36-38]. The extensive studies related to SAs expression 
level and cell apoptosis have been done by Dr. Susan L. Bellis research group focusing on 
the ST6Gal-I sialyltransferase [20, 39-41]. The decrease of SA level regulated by ST6Gal-
I on TNFR1 Death Receptor has been reported to induce macrophages apoptosis [20]. 
ST6Gal-I regulated sialylation of β1 integrins can block cell adhesion to galectin-3 and 
protect cells against galectin-3 induced apoptosis [40]. Moreover, Fas mediated apoptosis 
in colon carcinoma cells can be diminished by sialylation of the Fas death receptor by 
ST6Gal-I [39]. One explanation of ST6Gal-I protecting cell against apoptosis can be 
explained by its inhibition of galectins blinding to underling galactose, which is reported 
to limit the life span of variety of cells [41]. In our study, the ST6Gal-I was found to 
decrease significantly after cell treated with atorvastatin, and meantime the cell apoptosis 
level elevated dramatically. Based on Dr. Bellis report, the reduction of ST6Gal-I level can 
partially contribute to atorvastatin induced macrophage apoptosis. Conversely, an increase 
of α-2,6 linked SAs was observed in the late apoptotic lymphocytes [19]. One explanation 
for this phenomenon was the redistribution of immature (intracellular) membranes onto the 
cell surface during cell apoptosis [19]. This scenario is supported by an earlier study, which 
demonstrated the exposure of ER resident proteins and sugars predominantly on the 
incompletely processed proteins in ER and Glgi [42]. In our study, we found that α-2,6 
linked SAs increased apparently on macrophage cell surface upon atorvastatin activation. 
The late apoptotic redistribution of the intracellular membrane may, at least in part, explain 
the increase of α-2,6 linked SAs on the cell surface upon atorvastatin stimulation. A further 
study to reveal the particular molecular mechanism is highly warranted. 
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Most studies on the sialylation status have been limited to SAs on the cell surface 
with the methods such as lectins labeling, metabolic labeling, and chemical modification 
[43]. Free SAs and conjugated SAs levels in the cell culture medium may change upon cell 
activation, such as releasing SAs from cells (surface). In addition, SAs biosynthesis may 
increase inside of the cells as well. Therefore, we quantitatively examined the free SAs and 
conjugated SAs level in the cell culture medium after atorvastatin treatment, which 
indicated SAs releasing fact related to cell function alteration. In addition, we quantified 
the total SAs in the cells as well.  
So far, few studies tried to quantify the SAs trimmed off from cell surfaces [6, 44]. 
However, the quantification methods used were often with complicated sample preparation 
procedures, such as enzymatic or acid digestion, sample concentration, and SA 
derivatization. The DMB derivatization was mainly used for the quantification of SAs [44-
48]. However, the derivatization involves both high temperature and acidic conditions, 
which can hydrolyze part of the conjugated SAs, and severely interrupt the quantitative 
accuracy of a small amount of free SAs in the cell culture medium. In our study, we 
developed a new LC-MS/MS method for direct quantification of SAs in the cell culture 
system. In this method, the free SAs in the medium can be directly analyzed after simple 
centrifugation, and no any sample purification or concentration step is needed. Conjugated 
SAs in the medium or cell lysate were efficiently hydrolyzed with 2 M acetic acid at 80 oC 
for 90 min (data is not shown) followed by direct LC-MS/MS analysis. As a result, there 
were no significant changes for free SAs and conjugated SAs in the medium after 
atorvastatin treatment, indicating that no apparent sialidases activity changed during this 
process. However, the amount of total cellular SAs increased from 369 ± 29 ng/mL to 1080 
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± 50 ng/mL upon cell activation. Both confocal microscope and flow cytometry studies 
above revealed increasing α-2,6 linked SAs on the cells, indicating that the α-2,6 linked 
SAs was the major contributor for the total cellular SAs increase. Our western blot analysis 
of sialyltrasferases showed high level of ST6GalNAc-II, indicating it may be the major 
contributor for the increase of α-2,6 linked SAs. Overall, the newly developed LC-MS/MS 
method was successfully applied to sensitively quantify both free and total SAs in the 
culture medium and cell lysate. 
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3.5 Conclusion 
We profiled SAs dynamics in the whole culture system in the normal and 
atorvastatin treated conditions. α-2,3 Linked SAs were found predominant on the cell 
surface of Raw 264.7 cells under the normal condition and unchanged upon atorvastatin 
treated. In comparison, α-2,6 linked SAs were obscure but increased dramatically on the 
cell surface after atorvastatin treatment. In addition, the total SAs of the cells were 
significantly increased, while the SAs in the cell culture medium were unchanged after cell 
treated with atorvastatin. This is the first time of comprehensively analysis of cell surface 
SAs of their levels and linkages, free, conjugated and total SAs in the culture medium, and 
total SAs in the cells by combination of confocal microscopy, flow cytometry, and LC-
MS/MS, which provide a sensitive, specific and systematic way to globally study SAs in 
the cell culture system. This work will contribute to a better understanding of the 
physiological and pathological roles of SAs in macrophages and the immune system as 
well. In general, the reported methods can be expanded to study SAs status of any kind of 
cells of interests.  
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CHAPTER IV 
SIALYLATION AND DESIALYLATION DYNAMICS OF 
MONOCYTES UPON DIFFERENTIATION AND POLARIZATION 
TO MACROPHAGES 
 
  
4.1 Introduction 
Macrophages display remarkable plasticity that allows them to acquire functionally 
distinct phenotypes and take part in a large number of physiological and pathological 
processes [1]. Monocytes are precursors for tissue macrophages, in replenishing resident 
macrophages under normal states and in response to inflammation signals by quickly 
moving to the sites of infection and dividing/differentiating to macrophages in the tissues. 
Further, macrophages can be phenotypically polarized to classically (M1) or alternatively 
(M2) activated cells, both of them represent phenotypic extremes of macrophage 
differentiation [2,3]. These cells are often characterized by the expression of their specific 
cell surface protein markers, secreted cytokines and 
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chemokines, and transcription and epigenetic pathway. However, the precisely molecular 
determinants in mediating macrophage phenotypic heterogeneity and functional plasticity 
are still largely unknown.   
A density layer of glycans is expressed on the macrophage cell surface. Lines of 
evidence have hinted to potential roles of cell-surface glycans in the functions of 
macrophages [4]. SAs are a family of 9-carbon containing acidic monosaccharides and 
often terminate cell surface glycans of either glycoproteins or glycolipids. The C-5-amino 
derivative represents the well-known neuraminic acid, and its amino functional group can 
be either acetylated (N-acetylneuraminic acid, Neu5Ac) or glycolylated (N-
glycolylneuraminic acid, Neu5Gc). The most abundant SA is Neu5Ac. They exist on either 
N- or O-linked glycans, being attached to either Gal, or GalNAc units via α-2,3 or α-2,6 
linkage, which are synthesized by specific enzymes [5]. Accumulated evidences indicated 
that cell surface SAs can dramatically impact cell properties and represent different cellular 
statuses [6]. Therefore, the expression levels and linkages of SAs, named as sialylation 
status, may be biomarkers of specific cell status/population of macrophages and may be 
directly involved in macrophages functions as well.  
The linkage and expression level of cell surface SA are controlled by both the 
sialylation pathway catalyzed by specific sialyltransferse enzymes and the desialylation 
process catalyzed by specific sialidase enzymes and environment cues. In this study, we 
systematically investigated the sialylation and desialylation profiles of human monocytic 
leukemia cell line THP-1 after differentiation to M0 macrophages and polarization to M1, 
and M2 macrophages (Figure 20). THP-1 monocytes were induced with phorbol 12-
myristate 13-acetate (PMA) to differentiate into macrophages (M0), and further polarized 
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with LPS and IFN-γ to generate M1 macrophages, with IL4 and IL13 to generate M2 
macrophages [7,8]. Cell surface SA reflecting both sialyltrasferase and sialidase activities 
was examined by flow cytometry with specific lectins, MAA and SNA. Further, the 
siaoglycoconjugates synthesized inside the cells were selectively labeled with the FITC-
labeled lectins and imaged by confocal microscopy. Moreover, the expression level of 
sialyltransferases related to the sialylation status of the cells was confirmed by western 
blot, and the SA amount inside the cell was determined by LC-MS/MS. On the other hand, 
the desialylation level of the cells was examined by measuring free SA released in the 
media and the sialidase activity with the exogenous substrates. Overall, profiling 
macrophage cell surface sialylation and desialylation status will contribute to delineate 
macrophage diversity and define their phenotypes and functions. 
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Figure 20: Systematically investigation the sialylation and desialylation profiles of 
human monocytic leukemia cell line THP-1 after differentiation to M0 macrophages and 
polarization to M1 and M2 macrophages.   
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4.2 Materials and methods 
4.2.1 Materials 
N-Acetyl-D-neuraminic acid (SA, 98%) was supplied by Rose Scientific Ltd. 
(Edmonton AB, Canada). N-Acetyl-D-neuraminic acid-1,2,3-13C3 (13C3-SA, 99%), 
phorbol 12-myristate 13-acetate (PMA), lipopolysaccharides from Escherichia coli (LPS), 
4',6-diamidino-2-phenylindole (DAPI), propidium iodide (PI), RIPA buffer, protease 
inhibitor cocktail, rabbit anti-ST6Gal-I antibody, rabbit anti-ST6GalNAc-II antibody, 
rabbit anti-ST6GalNAc-VI antibody, rabbit anti-ST3Gal-IV antibody, rabbit anti-ST3Gal-
VI antibody,  and goat anti-rabbit IgG-peroxidase antibody were purchased from Sigma-
Aldrich Inc. (St. Louis, MO, USA). Rabbit anti-ST3Gal-I antibody and rabbit anti-ST3Gal-
V antibody were from Fisher Scientific (Hanover park, IL, USA). Rabbit anti-Human 
recombinant IFN-γ, IL-4 and IL-13, and FITC labeled mouse anti-human CD11b antibody 
were obtained from Life Technologies (Grand Island, NY, USA). FITC labeled MAA 
lectin was from bioWORLD (Dublin, OH, USA). FITC labeled SNA lectin was provided 
by Vector Laboratories (Burlingame, CA, USA). 4-Methylumbelliferyl N-acetyl-α-D-
neuraminic acid (4-MU-NANA) sodium salt was purchased from Carbosynth LLC (San 
Diego, CA, USA). GM3 ganglioside was obtained from Avanti Polar Lipids (Alabaster, 
AL, USA). Cytokine analysis was performed by EVE technologies (Calgary, Alberta, 
Canada). 
 
4.2.2 Cell differentiation and polarization 
THP-1 monocytes, obtained from American Type Culture Collection, were 
cultured in RPMI-1640 medium (Cleveland Clinic Core Facility, Cleveland, OH, USA) 
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supplemented with 10% fetal bovine serum (Life Technologies, Grand Island, NY, USA) 
and 1% penicillin/streptomycin (Cleveland Clinic Core Facility, Cleveland, OH, USA) in 
a humidified atmosphere containing 5% CO2 at 37 oC. The differentiation of THP-1 
monocytes to macrophages was accomplished by PMA stimulation for 48h. To generate 
M1-polarized macrophages, LPS (100 ng/mL) and IFN-γ (20 ng/mL) were added at the 
last 18 h of PMA treatment. To generate M2-polarizedmacrophages, IL4 (20 ng/mL) and 
IL13 (20 ng/mL) were added at the last 18 h of PMA treatment [7, 8]. In order to quantify 
SA in the medium, FBS was removed from culture medium before the addition of PMA. 
 
4.2.3 Flow cytometric analysis 
To determine cell surface SAs, cells were washed with cold PBS, and then 
incubated with 50 μL of FITC labeled MAA (10 μg/mL) or SNA (5μg/mL) for 15 min at 
room temperature in dark. Cells were subsequently washed, re-suspended in cold PBS and 
analysed by a FACSCantoⅡ flow cytometer operated through BD FACSDiva software 
(BD Bioscience, Mountain View, CA, USA). For the CD11b staining, cells were washed, 
suspended in cold FACS buffer (PBS, 0.5% BSA, and 0.1% sodium azide), and blocked 
with 10% heat inactivated human serum for 20 min on ice. Cells were then centrifuged and 
suspended in 100 μL cold FACS buffer with 5 μL FITC labeled CD11b antibody. After 30 
min incubation on ice, cells were washed and re-suspended in cold FACS buffer for flow 
analysis. 
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4.2.4 Confocal microscopy 
THP-1 monocytes were seeded on cover slips in 6-well plate at a density of one 
million cells/well, and then differentiated and polarized to different type of macrophages 
following the method described in the Cell Differentiation and Polarization section. To 
determine SA expression of the macrophages, cells were washed with cold PBS, and fixed 
with 4% PFA for 10 min.  Excess PFA was removed, and optionally the cells were 
permeabilized with 0.2% TritonX-100 for 10 minutes to expose SAs inside the cells. Then 
cells were stained with MAA-FITC (10 μg/mL) or SNA-FITC (5 μg/mL) for 15 min, 
followed by 2 min DAPI stain. Unbound lectin and DAPI were washed off with PBS, and 
cover slips were mounted on ProLong Gold Antifade reagent. Images were acquired at a 
60 × magnification using a Nikon A1Rsi confocal microscope, and data analysis was 
performed using NIS-Elements software (Nikon Instruments Inc., Melville, NY, USA). To 
determine SAs expressed on THP-1 monocytes, the cover slips placed in 6-well plate were 
first treated with 1% alcian blue solution (Electron Microscopy Sciences, Hatfield, PA, 
USA) for 30 min, and then one million of cells in PBS buffer were seeded in each well. 
After standing for 20 min, the cells deposited on cover slips were fixed with 4% PFA and 
then followed the steps for macrophages staining. 
 
4.2.5 LC-MS/MS analysis 
SAs in the media and cell lysates were quantified according to our established 
protocol [9]. Briefly, the chromatography was performed on a Nexera liquid 
chromatography system (Shimadzu, Columbia, MD, USA). The separation of SA and 13C3-
SA (internal standard, IS) was carried out by a Primesep D column (2.1 x 100mm, 5 μm; 
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SIELC Technologies, Prospect Heights, IL, USA) in a binary gradient mode with phase A 
containing 10 mM ammonium formate and 0.1% formic acid in water, and phase B 
composed of 90% acetonitrile, 10% water, 3 mM ammonium formate, and 0.04% formic 
acid. The gradient elution started at 10% phase B and changed linearly to 100% B from 1.1 
min to 4.0 min. To equilibrate the column, the gradient sharply dropped to 10% B from 6.0 
min to 6.1 min and maintained for 3 min. The MS detection was carried out by a Qtrap 
5500 mass spectrometer equipped with eletrospray ionization source (AB SCIEX, 
Framingham, MA, USA). The quantitative transitions were set at m/z 308 → 87 for SA, 
and 311 → 90 for IS. The data acquisition and processing were conducted using Analysis 
1.6.1 software. The calibration range for SA was from 2.00 to 1.00×103 ng/mL. 
To quantify free SA in the medium, 95 μL of culture medium was spiked with 5 μL 
of IS, and then 5 μL of the mixture was subjected to LC-MS/MS analysis. The total SA in 
culture medium was determined by hydrolyzing the sample with 2 M acetic acid (1:1) at 
80 oC for 90 min, and then mixing 95 μL of the lysate with 5 μL of the IS before analysis. 
For quantification of cell lysate SA, the sample at a density of 1×106 cells/mL was 
untrosonicated to obtain homogeneous mixture and then followed the procedure of total 
SA quantification for culture medium. 
 
4.2.6 Sialidase activity measurement 
Cells in the indicated conditions were collected and two millions of the cells were 
suspended in the reaction buffer, which containing 0.05 M sodium acetate at pH 4.4, 0.1% 
Triton X-100, and 0.1% BSA. The activity of NEU1 and NEU3 were determined by the 
addition of 0.125 mM 4-MU-NANA and 0.250 mM ganglioside GM3, respectively [10-
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12]. After1 h incubation at 37 oC, the reaction mixtures were centrifuged to remove cellular 
debris, and the supernatants were precipitated with acetonitrile at 1:3 ratio to remove the 
soluble proteins. Then 20 μL of the supernatant was mixed with 5 μL of IS and 75 μL of 
PBS, and 5 μL of the mixture was subjected to the LC-MS/MS analysis. Protein 
concentrations in each assay were measured by the Bradford method using a protein assay 
kit (Bio-Rad, Hercules, CA, USA). One unit of sialidase activity was defined as one nmol 
of free SA that released from one mg of total protein per hour at 37 oC. 
 
4.2.7 Western blot 
Cells in the indicated conditions were lysed with a mixture of RIPA buffer and 
protease inhibitor cocktail (1:100, v/v) on ice for 5 min, and the cell lysates were collected 
and clarified by centrifugation at 15,000 g at 4 oC for 10 min. Protein concentrations were 
measured by Bradford method using a protein assay kit. Proteins at amount of 30 μg/sample 
were separated on SDS-12% polyacrylamide gels and then transferred to polyvinylidene 
difluoride membrane. The membranes were blocked with 5% nonfat milk for 1 h at room 
temperature, followed by incubation with primary antibodies at 4oC overnight. After 
washing with tri-buffered saline containing 0.05% Tween 20 (TBS-T) buffer, the 
membrane was probed with specific secondary antibodies conjugated with horseradish 
peroxidase for 1 h at room temperature. Protein detection was accomplished by using the 
ECL Prime kit (Pierce) with the LI-COR Odyssey Fc imaging system. 
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4.3 Results 
4.3.1 Cell surface SA analyzed by flow cytometry 
To determine the cell surface sialylation level during THP-1 monocytes 
differentiation, cells were incubated with PMA at 10, 20, and 50 ng/mL for 48 h. The 
differentiation of THP-1 monocytes to macrophages was confirmed by the expression of 
CD11b, which showed more than 80% positive after 48 h treatment with PMA (data is not 
shown) [13, 14]. SA on the cell surface is found most commonly linked to underlying 
sugars with α-2,3 and α-2,6 linkages [15]. To examine the cell surface sialylation status, 
we performed flow cytometry to distinctively measure SA with different linkages on the 
THP-1 monocytes and macrophages by using MAA-FITC and SNA-FITC labeling, which 
selectively recognize α-2,3 and α-2,6 linked SA, respectively. As observed from Figure 21 
A and B, both MAA and SNA peaks left shifted after cells treated with PMA, suggesting 
the decrease of both α-2,3 and α-2,6 linked SA on the cell surface of the differentiated 
macrophages. The statistical analysis showed the mean fluorescent intensity (MFI) of 
MAA labeled α-2,3 SA decreased more than 20% and SNA labeled α-2,6 SA decreased 
more than 30% (Figure 21 C). The change of cell surface SA was not related to PMA 
concentration as observed in Figure 21 C. 
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Figure 21: Cell surface SAs determined by flow cytometry. (A): THP-1 monocytes 
were labeled with MAA-FITC (10 μg/mL) or SNA-FITC (5 μg/mL). (B): M0 macrophages 
were obtained by differentiation of THP-1 monocytes with PMA at 10 ng/mL for 48 h, and 
then the cells were labeled with MAA-FITC (10 μg/mL) or SNA-FITC (5 μg/mL). (C): 
Statistical analysis of three independent experiments (n=3). Significantly different values 
(*P < 0.05, **P < 0.01) were obtained by SPSS 19.0 with paired-samples t test. 
 143 
 
Next, the polarization of M0 macrophages was carried out by the stimulation with 
M1 cytokines (LPS and IFN-γ) or M2 cytokines (IL-4 and IL-13) with PMA at 
concentrations of 10, 20, and 50 ng/mL, respectively. Cytokines including GM-CSF, IL-
1β, IL-6, IL-12, and TNFα were analyzed before and after polarization (Figure 22). The 
change of cell surface SA was examined by flow cytometry by using MAA-FITC and 
SNA-FITC labeling too. As a result, no significant peak shift was observed for either MAA 
or SNA labeling compared to M0 macrophages (data is not shown), suggesting the cell 
surface SA content was unchanged, which may be not crucial during the macrophage 
activation. The sialidase from Arthrobacter ureafaciens was used to release cell surface 
SA from M0, M1 and M2 macrophages. However, due to the insufficient releasing of α2,6-
linked SA in the neutral pH, no further study was performed with exogenous sialidase 
(Figure 23). 
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Figure 22: Cytokine analysis of THP-1 derived M0, M1 and M2 macrophages (n=3). THP-1 monocytes were seeded in 12-well 
plate at a density of 0.5 million cells per well. After differentiation with PMA at 10 ng/ml and polarization with M1 and M2 cytokines, 
GM-CSF, IL-1β, IL-6, IL-12, and TNFα in the medium were quantified with human cytokine array offered by EVE technologies. As a 
result, M1 has higher concentrations in IL-1β, IL-6, IL-12, and TNFα compared to M0 and M2. While M0 and M2 show similar cytokine 
profile, except granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a specific marker for M1. 
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Figure 23: Cell surface SA profile after sialidase treatment. THP-1 derived M0, M1 
and M2 macrophages were incubated with sialidase from Arthrobacter ureafaciens in PBS 
buffer for 1h. Then α2,3-linked SA was labeled with MAA-FITC (10 μg/mL), and α2,6-
linked SA was labeled with SNA-FITC (5 μg/mL). The nuclei were stained with DAPI (1 
μg/mL). As is observed, α2,3-linked SA is more prone to sialidase treatment, while α2,6-
linked SA shows a less releasing efficiency. 
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4.3.2 Cellular SA expression determined by confocal microscopy 
To visualize the SA expression, the cells were permeablized to detect SA inside the 
cells and without permeabilization to determine the cell surface SA only. As shown in 
Figure 24 B and D, both MAA labeled α 2,3-linked SA and SNA labeled α2,6-linked SA 
were found highly expressed inside the cells after PMA treatment for 48 h, indicating that 
the sialylation became more active in the differentiated macrophages, and this change was 
not related to PMA concentrations (data is not shown). However, all the M0, M1, and M2 
macrophages showed a similar expression level of SA inside the cells. We were not able 
to determine any difference in fluorescent intensity of cell surface SA between monocytes 
and M0, M1, and M2 macrophages (Figure 24 A and C).  
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Figure 24: The SA expression level examined by confocal microscopy. The 
differentiation of THP-1 monocytes was carried out by incubation with 10 ng/mL of PMA 
for 48 h. M1 and M2 polarizing cytokines were added at the last 18 h of PMA 
differentiation. Cells in (B) and (D) groups were permeabilized with Triton X-100 prior to 
MAA-FITC (10 μg/mL) or SNA-FITC (5 μg/mL) stain. (A): α2,3-linked SA on the cell 
surfaces was labeled with MAA-FITC. (B): Cells were permeablized first, and then α2,3-
 148 
 
linked SA on the cell surfaces and inside the cells was labeled with MAA-FITC. (C):  α2,6-
linked SA on the cell surfaces was labeled with SNA-FITC. (D): Cells were permeablized 
first, and then α2,6-linked SA on the cell surfaces and inside the cells was labeled with 
SNA-FITC. The results were reproduced at least in three independent experiments. The 
scale bar represents 10 μm. 
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4.3.3 LC-MS/MS quantification of SA in the culture media and cell lysates 
The SA concentrations in the culture media and cell lysates were measured by LC-
MS/MS. The results are listed in Figure 25, which shows the dramatic increase of SA in 
the cell culture media and cell lysates with PMA treatment in 48 h. For example, after cells 
incubated with 10 ng/mL PMA for 48 h, the free SA in the medium reached to 12.83 ± 0.70 
ng/mL compared with 4.18 ± 0.05 ng/mL in non-differentiated cells; the total SA in the 
medium increased in a similar manner, which changed from 28.13 ± 1.36 ng/mL to 73.50 
± 2.55 ng/mL. The SA in the cell lysate at a density of 1 × 106 cells/mL was found to be 
728 ± 17 ng/mL in the monocytes and increased to 1310 ± 203 ng/mL in the differentiated 
macrophages. However, the concentration of PMA did not show any significant effect on 
the SA concentration in either culture media or cell lysates.  
Upon polarization of M0 macrophages with M1 and M2 cytokines, no significant 
change of SA in the medium was found (Figure 25 D and E). While SA in the cell lysates 
changed depending on the initial PMA concentration used to differentiate monocytes. The 
SA concentration in M1 macrophages decreased significantly compared with M0 
macrophages at the PMA concentration of 50 ng/mL while the SA amount increased in the 
M2 macrophages, and the significant difference was found at PMA concentrations of 20 
and 50 ng/mL. 
  
 150 
 
  
 
  
 
  
Figure 25: SA levels in the cell culture media and cell lysates determined by LC-
MS/MS. Free SA in the media was determined by LC-MS/MS directly. The medium 
samples were hydrolyzed with acetic acid prior to LC-MS/MS analysis to quantify the total 
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SA.  For cell lysate SA quantification, cells were ultrasonicated first to obtain 
homogeneous mixture, and then followed by acid hydrolysis and LC-MS/MS analysis. (A): 
Free SA in the PMA differentiated macrophages (M0) culture media. Cells were cultured 
at a density of 1 million cells/2 ml medium and treated with vehicle (concentration 0 
ng/mL) or PMA at concentrations of 5, 10, 20, 50, 100 ng/mL. The media were collected 
at 24, 48, and 72h for LC-MS/MS analysis. (B): Total SA in the M0 macrophages culture 
media. (C): The SA in the M0 cell lysates. (D): Free SA in the M0, M1 and M2 
macrophages culture media. Cells were incubated with PMA at concentrations of 10, 20, 
and 50 ng/mL for 48 h. The M1 and M2 polarizing cytokines were added in the last 18 h 
of PMA differentiation. (E): Total SA in the M0, M1 and M2 macrophages culture media. 
(F): The SA in the M0, M1, and M2 cell lysates. The results were repeated in at least three 
independent experiments. Data is a representive from one experiment with three samples 
(n=3). The statistical analysis was performed using SPSS 19.0 with paired-samples t test. 
*P < 0.05, **P < 0.01. 
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4.3.4 Sialidases activity assay 
During the differentiation of THP-1 monocytes to macrophages, free SA in the 
culture medium increased in all three conditions after 48 h treatment, which was 
corresponded with the decease of SA on the cell surface. The decreasing could be attributed 
to the elevated desialylation process, which was catalyzed by specific sialidases located in 
lysosomal, cytosol and cell surface. It was known that the lysosomal Neu1 and plasma 
membrane-associated Neu3 are two major forms of sialidases in mammalian cells [16]. In 
this study, the sialidase activity of Neu1 and Neu3 in THP-1 monocytes and M0 
macrophages was determined using the exogenous sialidase substrates 4-
methylumbelliferyl N-acetyl-α-D-neuraminic acid (4-MU-NANA) sodium salt and 
ganglioside GM3, respectively [10-12, 17]. For control analysis, the cells were incubated 
with only reaction buffer to determine the desialylation level of endogenous 
sialylconjugates under the same condition. As shown in Figure 26, both endogenous group 
and 4-MU-NANA group indicate the sialidase activity increased significantly after 24 h 
differentiation, and the highest activity reached in 48 h. For example, after 48 h 
differentiation the sialidase activity increased from 0.97 ± 0.02 units to 5.08 ± 0.03 units 
in endogenous group, from 12.01 ± 0.54 units to 28.48 ± 2.28 units in 4-MU-NANA group, 
while from 4.17 ± 0.29 units to 5.97 ± 0.38 units in the GM3 group. These data suggest 
Neu1 is the major contributor for the sialidase activity during THP-1 monocytes 
differentiation. Since no apparent change of free SA in the medium during M1 and M2 
macrophages polarization, and thus the sialidase activity was not examined in these 
processes. 
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Figure 26: Comparison of sialidase activity in THP-1 monocytes and PMA 
differentiated M0 macrophages. The monocytes were differentiated with PMA at 10 
ng/mL, and the sialidase activity was measured at 24, 48, and 72 h with 4-MU-NANA and 
GM3 as substrates for NEU1 and NEU3, respectively. In the endogenous group, cells were 
incubated with only reaction buffer, and the results represented sialidase activity with 
endogenous sialylconjugates as substrates. This results were repeated in three independent 
experiments. Data is a representative from one experiment with three samples (n=3). 
Significantly different values (*P < 0.05, **P < 0.01) were obtained by SPSS 19.0 with 
paired-samples t test. 
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4.3.5 Sialyltransferase expression level determined by Western blot 
The LC-MS/MS results of increased cellular SA were in accordance with the 
enhanced sialylation inside the cells as observed by confocal microscopy above. Therefore, 
we performed Western Blot assays to distinctively study the effect of sialyltransferases in 
THP-1 monocytes and the differentiated and polarized macrophages. Sialyltransferases for 
α2,3-linkages, including ST3Gal-I for O-glycan, ST3Gal-IV for both O-glycan and N-
glycan, ST3Gal-V for glycolipid, and ST3Gal-VI for N-glycan, were compared. For α2,6-
linked SA synthesis, sialyltransferases including ST6Gal-I for N-glycan, ST6GalNAc-II 
for O-glycan, and ST6GalNAc-VI for glycolipids were investigated. As a result (Figure 
27), both ST3Gal-I and ST3Gal-V showed a low expression level in the monocytes, but 
increased in the M0, M1 and M2 macrophages. While ST3Gal-IV and ST3Gal-VI were not 
detected in all the cells, which may indicate the low abundance of α2,3-sialylated N-
glycans in THP-1 cells. In terms of α2,6-linked SA, ST6Gal-I and ST6GalNAc-II increased 
the expression in the macrophages compared to the undifferentiated monocytes. However, 
the expression of ST6GalNAc-VI decreased dramatically in the macrophages. The 
tremendous change of ST3Gal-V and ST6GalNAc-VI suggests the vast reorganization of 
sialylated glycolipids during monocytes differentiation and polarization. 
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Figure 27: Western blot analysis of sialyltransferases in THP-1 monocytes and the 
derived macrophages. THP-1 monocytes were incubated with 10 ng/mL of PMA for 48 h 
to obtain M0 macrophages. The M1 and M2 macrophages were polarized by addition of 
the corresponding cytokines in the last 18 h of PMA differentiation. Sialyltransferases 
including ST3Gal-I, ST3Gal-V, ST6Gal-I, ST6GalNAc-II, and ST6GalNAc-VI were 
determined by western blot using rabbit anti-ST3Gal-I antibody, rabbit anti-ST3Gal-V 
antibody, rabbit anti-ST6Gal-I antibody, rabbit anti-ST6GalNAc-II antibody and rabbit 
anti-ST6GalNAc-VI antibody, respectively. 
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4.4 Discussion 
Monocytes originate in the bone marrow and are then released into the peripheral 
blood, where they circulate for several days before differentiation to macrophages, 
contributing to the host defense and tissue remodeling and repair [18]. SA terminates most 
of the glycan structures on the cell surfaces and secreted glycoconjugates. Consequently, 
it is involved in variety of physiological and pathological activities of immune cells. 
However, so far there is no systematic study related to the sialylation and desialylation 
status of monocytes and the corresponding macrophages. In this study, THP-1 monocytes 
were used to comprehensively profile the SA level change during monocytes differentiate 
to M0 macrophages and further polarize to M1 and M2 macrophages. The cell surface SA 
in both α2,3- andα2,6-linkages were decreased during the process, and this result was 
further supported by the elevation of cellular Neu1 activity and increase of free SA 
concentration in the medium. Next, SA synthesis increased in the macrophages, which was 
indicated by confocal images of lectin labeled siaoglycoconjugates inside the cells and the 
SA amount inside the cells determined by LC-MS/MS. These findings were further 
supported by the change of sialyltransfereses with Western Blot assays which showed the 
elevated expression of ST3Gal-I, ST3Gal-V, ST6Gal-I, and ST6GalNAc-II while the down 
regulation of ST6GalNAc-VI (Figure 27). It was found that Monocyte-characteristic 
surface sialoglycoproteins disappear during in vitro differentiation of monocytes to 
adherent macrophages, which was considered to a parameter for the conversion of 
monocytes to macrophages [19]. Our flow cytometry results were consistent with this 
finding, that showed the decrease of both α2,3- and α2,6-linked SA on the cell surfaces 
during THP-1 monocytes differentiate to macrophages.  
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A previous study focused on the endogenous sialidases of human monocytes during 
differentiation to macrophages show a significant increase of NEU1 and NEU3 as analyzed 
by PCR and Western Blot [12]. In our study, we provide the first evidence that the increase 
of Neu1 activity is associated with the increase of free SA released in the cell culture 
medium. Neu1 catalyzes lysosomal catabolism of sialylated glycoconjugates. During the 
differentiation of monocytes or the monocytic cell lines, THP-1, to macrophages, the 
majority of Neu1 were translocalized from lysosomes to the cell surface. The suppression 
of Neu1 expression in the THP-1 derived macrophages by small interfering RNA or with 
anti-Neu1 antibodies was reported significantly reduced the ability of the cells to engulf 
bacteria or to produce cytokines [20]. Whereas, treatment of cells with purified Neu1 was 
able to reduce surface sialylation and restore the phagocytic ability [21]. However, there is 
no difference between medium free SA of M0, M1, and M2 macrophages. This observation 
suggests the similarity of sialidase activity between these subtypes of macrophages.  
The relative activity of sialyltransferases influences the expression of sialytated 
molecules on the cell surfaces and secreted sialoglycoconjugates, and may contribute to 
the definition of the glycosylation pattern of monocytes and the corresponding 
macrophages. However, no systemic studies have focused on the SA pattern changing 
along monocytes differentiation and polarization so far. In our study, the increasing of the 
cellular SA level in the differentiated M0 macrophages was confirmed by both LC-MS/MS 
and confocal microscopy, while the difference between M0, M1, and M2 macrophages 
could be only distinguished by LC-MS/MS on the cellular SA level, which is possibly due 
to the sensitivity of the different detection method. The Western Blot results showed 
sialyltransferases, including ST6Gal-I, ST6GalNAc-II, ST6GalNAc-VI, ST3Gal-I, and 
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ST3Gal-V, contributed to the SA variation in the differentiated and polarized macrophages. 
The elevation of ST6Gal-I and ST3Gal-I indicated the enhanced synthesis of α2,6-
sialylated N-glycans and α2,3-sialylatedO-glycans, respectively. Similar to our 
observation, both enzymes were found upregulated during monocytes differentiate to 
dendritic cells (DCs) at their mRNA level [22]. ST6GalNAc-II has been reported to be 
increased in the LPS treated human macrophages and atorvastatin treated Raw 
macrophages, suggesting the increase expression of α2,6-sialylated O-glycans may be 
related to cell activation status [9, 23]. ST3Gal-V is responsible for the formation of GM3 
using lactosylceramide as the substrate, and previous reports showed the enhancing of 
GM3 expression during differentiation of monocytes to macrophages [24, 25], which is in 
accordance with the rise of ST3Gal-V in our findings. ST6GalNAc-VI catalyzes the 
formation of α2,6-sialyltransferase involved in the synthesis of all α-series gangliosides, 
and the decrease of this enzyme level may be related to the well-recognized capability of 
macrophages to respond and alter a wide range of lipid products [26]. In our study, both 
ST3Gal-IV and ST3Gal-VI that catalyzing the formation of α2,3-linked SA on N-glycans 
were undetectable although the mRNA expression was reported in human peripheral blood 
monocytes [22]. This observation may result from either the low abundance of α2,3-linked 
SA on N-glycans, or the low sensitivity of the corresponding antibodies on the market.  
M1 macrophages showed a decreased level of cellular SA, whereas M2 
macrophages showed increased in compared to M0 macrophages. This interesting 
phenomenon may indicate the cell function change during cell differentiation. M1 
macrophages are known to be associated with acute inflammatory responses and M2 
macrophages are characterized with inflammatory responses and adaptive type I immunity 
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[27-29]. Previous studies indicated that the decrease of sialylation level is always 
associated with the increase of inflammatory response and vice versa [20, 21, 30-33]. For 
example, the anti-inflammatory activity of immunoglobulin G (IgG) is resulted from the 
sialylation of its Fc core polysaccharide, which could be reduced upon the induction of an 
antigen-specific immune response. Thus the differential sialylation may provide a switch 
from innate anti-inflammatory activity in the steady state to generate adaptive pro-
inflammatory effects upon antigenic challenge [30]. In term of immune cells, the 
suppression of Neu1 expression in THP-1 derived macrophages can significantly reduce 
the ability of the cells to engulf bacteria or to produce cytokines, while this inflammatory 
function can be restored by the treatment of sialidase [20, 21].  
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4.5 Conclusion 
We report a systematic investigation of sialylation and desialylation dynamics of 
monocytes after differentiation and polarization to macrophages. The lectin labeling, 
followed with flow cytometry and confocal microscopy detection gives the direct evidence 
of SA change regarding to α-2,3 and α-2,6 linkage. Moreover, LC-MS/MS provides a 
sensitive and accurate detection of released SAs in both culture medium and SAs 
synthesized inside the cells. Further, studies based on the levels of sialidases and 
sialyltransferases furnish a fundamental mechanism leading to the alteration of SA, which 
could be used to manipulate the differentiation and polarization of monocytes. This work 
will contribute to a better understanding of the physiological and pathological roles of SAs 
in the monocyte differentiation and polarization as well as the immune system. 
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CHAPTER V 
SUMMARY 
 
 
SAs often exist as the terminal sugars of glycan structures of cell surface 
glycoproteins and glycolipids. The level and linkages of cell surface SAs, which are 
controlled by both sialylation and desialylation processes and environment cues, can 
dramatically impact cell functions and represent different cellular statuses. Traditional 
approach for SAs study employed the SA binding proteins, lectins, which can specifically 
recognize SAs in certain linkages. However, the application of lectins is almost limited to 
the intact cells, and the bias in differentiation the change of SAs on the cell surface cannot 
be avoid due to the fact that SAs may exist both inside and outside the cell membrance, 
and also the spacial hindrance cannot be avoided. SA quantification was used in some 
researches to study SA amount change in different conditions. Quinoxilinone 
derivatization provides a sensitive and specific way to stuy total SA, as well as SA species. 
However, the high temperature and acidic condition make it  impossible to analyze only 
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the free SA part in matrice, such as cell culture medium and plasma, which contains large 
ratio of conjugated SA. Although several direct quatification methods had been developed 
for free SA determination, the most sensitive one reported had quantification limit of 100 
ng/mL and most of others could only detect SA in μg/ml. These methods may be good for 
patient samples with SSDs, which accumulated large amount of free SA, but not applicable 
for regular cell culture medium generally with free SA less than 10 ng/mL.  
In my study, firstly I developed two new LC-MS/MS methods for broad scope of 
SA quantification. The derivatiztion approach using a stable and inexpensive reagent DAT 
provides a stable product of SA with high MS response, proving a convenient and cost-
effective LC-MS/MS analysis of conjugated SA and free SA after protein depletion. In 
addition, trace amount of SA in the reagents including water was found in this study, which 
made it inaccurate to quantiy low concentration of SA. Therefor, the 13C3-SA was used as 
calibration standard to ensure the accuracy of the measurement. Last, this assay used 
UHPLC for separation of native/labeled SA and IS from matrix interference, and employed 
mass spectrometry in MRM mode for sensitive and selective detection. We have achieved 
a LLOQ of 20 ng/mL and a total running time of 4.2 min, which is the most sensitive and 
quick measurement for SA with derivatization. This method has been applied to quantify 
free SA in plasma samples from cardiovascular disease patients. We have found the 
increase of free SA in these patients compared to health individuals. However, more 
samples are required to make statistical conclusion.             
In order to work on large scale of samples, we further imporved SA quantification 
with a non-derivatization method. In this direct LC-MS/MS approach, cell culture medium 
can be analyzed directly after simple centrifugation, which provides the most accurate way 
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for free SA detection. This method is sensitive enough to quantify SA in 2 ng/mL in culture 
medium. However, one limitation for this method is the capability to separate SA 
analogues. It affords excellet resolution for Neu5Ac and Neu5Gc, while doesn’t work well 
when Neu5Ac loses the first carbon, which is the proposed physiological pathway for 
desialylation under oxidative stress; also it shows no retention when the hydroxyl group on 
the C-5 in Neu5Gc is substituted with glycine. However, all these problems can be resolved 
by DAT derivatization with LC-MS/MS quantification.   
LC-MS/MS has been proved to be a powerful tool to quantitatively stuy SA in the 
cell lysate, and both free and total SA in the culture medium. With the combination of flow 
cytometry and confocal microscopy using fluorescent lectins labeling for the intact cells, 
the sialylation status on the cell surface and inside the cells can be reveled, which offers a 
powerful approach to comprehensivly study sialylation status in different cellular 
conditions related to both physiological and pathological processes. With these approaches, 
we performed globally profiling of the sialylation status of macrophages and their release 
of SAs in the cell culture medium after atorvastatin treatment. Both flow cytometry and 
confocal microscopy results showed that α-2,3 linked SAs were predominant on the cell 
surface and changed slightly upon treatment with atorvastatin, while α-2,6 linked SAs were 
negligible in the normal culture condition but significantly increased after treatment. 
Meanwhile, the amount of total cellular SAs increased about three times upon treatment as 
determined by LC-MS/MS method, which further supported the observation from flow 
cytometry and confocal microscopy. These results indicated that the cell surface α-2,6 
sialylation status of macrophages changes distinctly upon atorvastatin stimulation, which 
may reflect on the biological functions of the cells. Moreover, the increase of α-2,6 linked 
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SA correlats well with the Annexin V postivie cell ratio, which suggests a possible 
correlation of SA and cell apoptosis.    
Next, we examined the sialylation and desialylation features during monocytes 
differentiate to macrophages. In this study, THP-1 monocytes were used as model cell line 
to differentiate to inactivated macropahgs (M0), then polarize to M1 and M2 macrophages 
under different stimuli. Interestingly, both α-2,3 and α-2,6 linked SAs on the cell surface 
were found to be decreased after monocytes were differentiated to macrophages, which 
was in accordance with the increased level of free SA in the cell culture medium and the 
elevated activity of endogenous NEU1 sialidase. Meanwhile, the siaoglycoconjugates 
inside the cells increased as confirmed by confocal microscopy and the total SA inside the 
cells increased as determined by LC-MS/MS. Western blot analysis showed higher 
expression levels of sialyltransferases, including ST3Gal-I, ST3Gal-V, ST6Gal-I and 
ST6GalNAc-II.  Further, upon polarization, the cell surface sialylation levels of M1 and 
M2 macrophages remained the same as M0 macrophages, while a slight decrease of 
cellular SAs in the M1 macrophages but increase in the M2 macrophages were confirmed 
by LC-MS/MS. 
 In summary, we developed two LC-MS/MS methods for broad scope of SA 
quantification. The derivatization method has been successfully applied to determine free 
SA in human plasma. The direct quantification approach has been combined with flow 
cytometry and confocal microscopy with lectin labeling to profile SAs in the cell culture 
system. LC-MS/MS can accurately quantify SA in the cell lysate and culture medium in a      
high throughtput fashion.  The SA linkages on the cell surface can be distinguished by flow 
cytometry and confocal microscopy with specific lectin labelings. The total SA amount in 
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the cell lysate provides a direct evidence of the consequence of sialyltransferases change, 
and the free SA in the medium can serve as an indicator for sialidases activity.  
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CHAPTER VI 
FUTURE PERSPECTIVE 
 
 
6.1 SAs related glycomics study 
Glycomic analyses seek to understand how a collection of glycans relates to a 
particular biological event. As described before, sialylated glycoconjugates participate in 
many biological process, from intracellular signaling to organ development and tumor 
growth. However, due to the fact that the understanding of the molecular functions of SAs 
in these physiologican and pathological processes are just emerging, it is not surprising that 
a clear understanding of the significance of nature’s SAs structural diversity is still missing. 
Our current studies have provided the evidence that SA amount and the linkages of the 
cells vary under different conditions. To understand the underling molecular mechanism 
and reveal new functions of sialylated structure in cell-cell communication, it will be 
valube to provide the detail sialylated glycan structure corresponding to different cellular 
conditions. 
High-resolution mass spectrometry is the primary technique for characterizing the 
structures of individual glycans when only small quantities are available, as is the case of 
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most glycomic studies. In this typical experiment, the sialylated glycoproteins from cell 
lysates can be enriched by lectin affinity column. Then the N-glycans are selectively 
released by endoglycosidase such as PNGase F, and the O-glycans are chemically released 
by reductive elimination due to no endoglycosidase has been found to work on O-glycan. 
The released glycan can be further permethylated to increase the MS response and to 
protect the SA structure. Alternatively, the glycans can be analyzed directly under negative 
mode or under positive mode after enzymatic desialylation. The detailed glycan sturctures 
can be elucidated by the combination of fragmentation pattern and further treatment with 
specific glycosidases.     
In my study, I have worked with bovine fetutin as a standard glycoprotein, and the 
released glycans were analyzed by Bruker Autoflex III MALDI-TOF-TOF mass 
spectrometry (Matrix Assisted Laser Desorption/Ionization-Time of Flight). As shown in 
Figure 28, this instrument is sensitive to detect glycoproteins on microgram scale with both 
native glyans or permethylated glycans. However, no glycans could be identified from the 
membrance proteins of THP-1 monocytes, which is likely due to the insufficient sample 
amount. In furture, mass spectrometry with higher sensitivity could be utilizd to further 
this study. 
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Figure 28: MALDI-TOF-MS spectra of glycans. (A) Permethylated N-glycans from 30 
μg fetuin. (B) Desialylated native N-glycans from 30 μg fetuin. (C) A N-glycan sample 
released from membrance protein of 10 million THP-1 cells.     
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6.2 Systematic and site-specific analysis of sialated proteins on the cell surface of 
immune cells 
Metabolic oligosaccharide engineering is a methodology that originated over two 
decades ago when the sialyltransferases were found to have the capacity to add modified 
SAs to glycoconjugates. This technology took a dramatic step forward when the modified 
ManNAc analogs were found to be able to incorporate into sialylated glycans. With this 
approach, the biorthogonal functional groups such as azide on the ManNAc or Neu5Ac 
analogs could be incorparated on the cell surface (Figure 29). Thus this functional group 
can further undergo covalent reaction with exogenous agents bearing complementary 
functionality which could enable systematic and site-specific analysis of sialated proteins 
on the cell surface of immune cells.  
The vast remodeling of cell surface sialoglycoproteins in the immune cells under 
different activation conditions has been reported in many researches. With the metabolic 
oligosaccharide engineering approach, the systematic and site-specific analysis of sialated 
proteins on the cell surface can be achieved. Specifically, the unnatural SA containing 
bioorthogonal functional group sucha as azide can be incorporated on the cell surface, and 
the glycans bearing this special sugar can be tagged by other agents to achieve labeling and 
furnish later separation. Then the cells can be lysed, and the labeled glycoconjugates can 
be pulled out with specific beads. These purified sialoglycans can be indentified by MS 
after PNGase F digestion. Further, if this enzymatic step is carried out in heavy water, all 
the Asn is converted to Asp with an 18O tag that can be identified by MS. Overall, this 
combined glycomics and metabolic engineering approach in immune cells has a great 
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potential in identifying new targets for disease treatment and vaccine development, and 
discovering effective biomarkers for disease detection and surveillance.    
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Figure 29: The principle of the site-specific identification of the cell surface N-
sialoglycoproteome by integrating metabolic labeling and MS-based glycomics 
techniques. (Chen W, Smeekens JM, Wu R. 2015. Systematic and site-specific analysis of 
N-sialoglycosylated proteins on the cell surface by integrating click chemistry and MS-
based proteomics. Chem Sci. 6: 4681-4689.) 
 
